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Mishra, Pragya, M.S., Purdue University, December 2014.  Pharmacist Collaborative 
Drug Therapy Management in U.S. hospitals.  Major Professor: Joseph Thomas III. 
The objectives for this study were to 1) assess the current extent, scope and 
perceptions of CDTM in U.S.  hospitals, 2) determine the associations between hospital 
characteristics, pharmacy director characteristics, and perceptions of CDTM, 3) 
investigate hospitals' short-term and long-term plans regarding CDTM, and 4) identify 
pharmacy directors' views about the major facilitators and barriers for CDTM in hospitals 
A self-administered written survey was mailed to a national random sample of 
hospitals stratified by state.  Pharmacy directors indicated whether any pharmacists were 
engaged in CDTM, what CDTM activities were permitted, and in what treatment 
categories CDTM was permitted.  Demographic data was also collected on both 
pharmacy director characteristics as well as hospital characteristics.  All respondents 
were asked to indicate their views of CDTM in terms of support for CDTM, financial 
impact of CDTM, strategic impact of CDTM and effect of CDTM regulations on 
practice, on a 5-point Likert-type scale, where 1 = strongly disagree, 2 = disagree, 3 = 
neutral, 4 = agree, and 5 = strongly agree.  The respondents also  indicated their plans for 
expanding CDTM in their hospitals on a 5-point Likert-type scale, where 1 = large 
decrease, 2 = slight decrease, 3 = no change, 4 = slight increase, and 5 = large increase. 
All respondents were asked in open-ended questions to indicate what they perceived to be 
the greatest barrier to CDTM and the greatest facilitator of CDTM. Logistic regression 
xv 
 
was used to assess associations between demographics and CDTM.  To test for response 
bias, chi-square tests compared CDTM and demographics of early and late respondents.  
An a priori alpha of 0.05 was used for all statistical tests. 
Of 1,024 surveys mailed, 84 were returned after failing to be delivered. Of the 
293 responses received, 7 were incomplete, leaving 283 usable surveys (30.1% adjusted 
usable response rate).  There were no significant differences in demographics or CDTM 
use in the earliest 1/3 and latest 1/3 of respondents indicating no response bias.  
Pharmacists were engaged in CDTM in 66 percent of hospitals.  Most hospitals allowed 
pharmacists to order laboratory tests (58.7%), adjust drug strength (57.9%) and change 
frequency of administration (53.8%).  Hospitals mostly permitted CDTM for 
Anticoagulation (52.4%), Infectious Diseases (44.8%) and Parenteral Nutrition (32.6%).    
It was seen that institution ownership, private hospitals were 3.3 (p<0.001) times, more 
likely than public hospitals to have pharmacist CDTM.  Likelihood of having CDTM was 
also positively associated with the population of the city in which the hospital was 
located as well as the number of beds in the hospital, with hospitals in larger cities and 
with a greater number of beds having a significantly higher chance of having CDTM as 
compared to smaller cities and hospitals.  Physician support for CDTM was identified as 






Collaborative drug therapy management (CDTM), is defined by the Alliance for 
Pharmaceutical Care as " a team approach to healthcare delivery whereby a pharmacist 
and prescriber establish written guidelines or protocols authorizing the pharmacist to 
initiate, modify or continue drug therapy for a specific patient." 
(www.ashp.org/DocLibrary/Affiliates/CDTM.aspx).  CDTM, also referred to as 
collaborative practice, allows pharmacists to use their specific drug therapy expertise, to 
augment care provided by other collaborating medical professionals in order to improve 
patient outcomes (Scott et al.  2003).  CDTM is characterized by an inter-disciplinary 
approach involving an agreement between patients and physicians to manage drug 
therapy regimens (Finley 2002), wherein "qualified pharmacists working within the 
context of a defined protocol are permitted to assume professional responsibility for 
performing patient assessments, ordering drug therapy-related laboratory tests, 
administering drugs; and selecting, initiating, monitoring, continuing, and adjusting drug 
regimens" (Anaya 2008). 
History of CDTM 
Prior to 1951, pharmacists had the legal right to prescribe drugs.  After the 
Durham- Humphrey amendment of 1951 was passed, prescribing by physicians and
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dispensing of drugs by pharmacists underwent a legal separation (Hammond, 2003).  As 
part of the  Durham- Humphrey amendment of 1951, pharmacists were prohibited from 
refilling prescription drugs without physician authorization (Marks, 1995; Swanns 1994).  
These changes were implemented to improve patient safety since, according to the law, 
any drug that could have harmful effects or cause dependency could only be dispensed by 
a health practitioner on receipt of a prescription.  This was done in order to prevent 
patients from abusing medications and it launched the beginning of the collaborative 
practice approach in which pharmacist services are integrated with services provided by 
other health care providers such as physicians and nurses to offer drug therapy 
management to patients (Marks 1995).  The main rationale for the collaborative practice 
approach was providing patients with more efficient care and of better quality 
(Hammond, 2003). 
The first CDTM program in the country was developed by the Indian Health 
Service. In 1973 a grant was used to set up the Pharmacist Practitioner Program under 
which pharmacists who had received the required training could collaborate with 
physicians to provide drug therapy management services such as patient monitoring 
between patient visits (Hammond 2003). This allowed physician visits to be spaced out 
more (Erickson 1977).  Under the Health Manpower Experimental Act of 1972,  allied 
health professionals in California were  allowed to shoulder additional responsibility 
under collaborative agreements (California Assembly Bill 1971-1984).  From 1981 to 
1994, California underwent a series of legislative changes, which ultimately resulted in 
granting all pharmacists practicing in California-licensed acute and intermediate health 
care facilities, clinics and managed care organizations, authorization to provide drug 
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therapy management. This allowed pharmacists to perform activities like adjusting drug 
dosage, ordering laboratory tests, performing physical assessments, and administering 
drugs and initiating drug therapy (California Assembly Bill 1971-1984).  In 1979, the 
state of Washington became the second state to authorize pharmacist participation in drug 
therapy management under the guidelines of a written protocol.  As of 2013,  pharmacists 
in Washington provide collaborative care community pharmacies, hospitals and managed 
care clinics (Christensen 1993).   
The American College of Clinical Pharmacy released a position statement in 1997 
supporting the use of pharmacist collaborative drug therapy management (CDTM) to 
improve the quality of patient care (Punekar 2003).  As of 1997, when the position 
statement was released, sixteen states had already passed laws that enabled pharmacist 
participation in drug therapy management through collaborations with physicians and 
other providers (Punekar 2003).  This number had expanded to thirty-eight states by the 
end of 2002.  The Practice Advisory on Collaborative Drug Therapy Management, which 
was approved by Academy of Managed Care Pharmacy in February 2012, stated that 
forty-seven states had collaborative drug therapy management (CDTM) legislation or 
regulations (Weaver 2013).  As of 2014, forty-eight states as well as the District of 
Columbia have laws allowing CDTM (Ryan 2014). 
Pharmacist Scope of Practice 
The role of the pharmacist has evolved to include patient education, drug therapy 
management, and pharmaceutical care, which are all facets of CDTM (Finley et al.  
2002).  Finley notes that the importance of having drug therapy experts is highlighted 
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when the increasing complexity of medication prescribing and the risk of adverse events 
due to drug interactions and medication errors are considered (Finley et al.  2002). 
The American Society of Health-Systems Pharmacists supports the CDTM 
approach to care (Giberson et al.  2011).  In the CDTM model, the physician is solely 
responsible for the diagnosis of a patient condition, while collaborating with the 
pharmacist to develop a specific management plan for an individual patient.  In this way, 
the responsibility for the care of the patient is shouldered by both the physician and the 
pharmacist (Scott et al.  2004).  According to the American Pharmacists Association, the 
activities performed by pharmacists under CDTM include initiating and modifying drug 
therapy, ordering and evaluating the results of laboratory tests, changing frequency of 
administration of drugs,  adjusting drug dosage,  and providing immunizations (Giberson 
et al.  2011).  In addition to the above, most pharmacists are also able to contribute to 
CDTM by performing medication and patient drug history reviews and performing 
physical assessments related to drug therapy, which include checking their vital signs 
(Practice Advisory on Collaborative Drug Therapy Management, AMCP) (Scott et al.  
2003).   
Legal Requirements for CDTM 
Since implementation of CDTM includes pharmacist duties sometimes considered 
to be outside their normal scope of practice, each individual state has been required to 
pass legislation that governs the extent and scope of  CDTM in that state (Finley et al.  
2002).  The Practice Advisory on Collaborative Drug Therapy Management, which was 
approved by Academy of Managed Care Pharmacy in February 2012, stated that forty-
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seven states had collaborative drug therapy management (CDTM) laws at that time 
(Weaver 2013).   
Literature Review 
Need for CDTM 
Approximately fifty percent of the U.S.  population takes a minimum of two 
medications every day with the Medicare population taking an average of over four 
medications each day (Menighan 2013).  Adverse drug events account for over one 
hundred thousand deaths per year and are the fourth leading cause of death in the US 
(Menighan 2013).  Medication errors exceed two and a half  million dollars a year and 
cost over hundred and seventeen billion dollars (Menighan 2013).  Menighan argues that 
prior investigators have reported  that patients are more satisfied with the care provided to 
them when the health care team includes a pharmacist.  Menighan also states that prior 
studies have reported improvement in patient outcomes as well as  reduction in health 
care costs when a pharmacist was included in the health care team. (Menighan 2013). 
 According to Carmichael et al, CDTM is beneficial to physicians since CDTM 
results in a decrease in the number of visits for patients of chronic diseases and allows 
physicians to invest more time in establishing patient relations and managing difficult and 
complicated cases.  Carmichael states that CDTM allows delegation of medication 
management to the pharmacist, who has the required skills and knowledge to support the 
physician’s therapy strategies (Carmichael et al.  1997).  He also posits that CDTM 
results in greater access to health care in the form of enhanced patient care via 
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pharmacist-physician collaborations, which has been reported to result in decreased drug-
related problems and reduced costs to the healthcare system (Carmichael et al.  1997).   
Impact of CDTM on Therapeutic Outcomes 
Several studies focusing on patients with congestive heart failure have reported 
benefits from CDTM (Gattis 1999; Kalisch 2010; Duncan 2006) .  Gattis and colleagues 
estimated the contribution of a pharmacist towards treating heart failure patients.  They 
determined if there was any decrease in patient mortality as well as the number of heart 
failure related events when a pharmacist was added to the heart failure management team 
of patients in clinic (Gattis et al.  1999).  The study utilized one hundred eighty-one heart 
failure receiving clinic based treatment.  All the participants were randomly assigned to 
either  an intervention group or a control group.  Patients in the control group received 
standard physician-provided care, while patients in the intervention group also received 
pharmacist care in addition to physician care.  This included drug therapy, making 
recommendations to the doctor, educating the patient about their health, and conducting 
follow-ups.  Gattis reported a significant reduction in patient mortality and heart failure 
events in the group receiving CDTM care as compared to the group receiving usual care.  
Other positive outcomes reported in the study were an increase in the number of  
angiotensin-converting enzyme inhibitor doses as well as increased use of vasodilators to 
treat resistant patients in the group that received pharmacist care in addition to patient 
care (Gattis et al.  1999).  
 A randomized clinical trial that focused on patients who were admitted to 
hospitals with heart failure reported a significant decrease in the number of new patient 
admissions to the hospital, a reduction in the total days the patient stayed in the hospital, 
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as well as improved  compliance with treatment for patients that had been  provided  
post-discharge care in the form of an interview with a pharmacist both on the day of 
discharge as well as on a monthly basis thereafter.  This lasted six months post-discharge 
(Kalisch et al.  2010).   
There have also been several reports of positive outcomes associated with 
pharmacist involvement in diabetes education, with Duncan reporting that patients with 
diabetes see their pharmacists seven times more often than they see their primary care 
physician (Duncan 2006).  Patients with Type-2 diabetes at The El Rio Health Center 
were provided care by a PharmD instead of a physician, only when the patients were 
referred to the residency-trained pharmacist by a physician (Leal et al.  2004).  The 
pharmacist evaluated patients, made recommendations,  prescribed medication and 
ordered laboratory tests (Leal et al.  2004).  Diabetes outcomes assessed by the 
pharmacist  included reduction in  A1C levels, which  refers to the level of hemoglobin 
A1C in the blood and is used as a way of estimating the average blood sugar 
concentrations for the patient in the previous two to three months.. Compared with the 
patient's original A1C levels,  Leal et al.reported statistically significant reduction in LDL 
(low-density lipoprotein) cholesterol levels, blood glucose levels, mean A1C levels and 
blood pressure values. The number of patients that had achieved their targeted A1C levels 
went up almost seven times, while the number of patients that had reached their goals for 
hypertension and LDL cholesterol levels increased by twenty-four and seventeen percent 
respectively (Leal et al.  2004).  Aspirin and ACE inhibitors (or angiotensin-converting-
enzyme inhibitors) were used for the treatment.  The use of aspirin increased by fifty -
three percent, and the use of ACE inhibitors showed a twenty-five percent increase, 
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leading the authors to conclude that inclusion of clinical pharmacists in health care teams  
for diabetes patients had a positive effect (Leal et al.  2004).   
Gerber et al. assessed the impact of three CDTM based models labeled Control, 
State, and Kaiser,  on medical costs, which the study defined as the cost of treatment for 
patients in two years. This study was conducted for diabetes patients receiving treatment 
at Kaiser Permanente of Southern California (Gerber et al.  1998).  In the Control model, 
pharmacists interacted with patients only on a need basis or by request.  In the State 
model the  pharmacists counseled patients on drug therapy, and the Kaiser model had  
pharmacists perform medication reviews, assess adherence as well as educate patients 
about their disease and drug therapy  (Gerber et al.  1998).  Both models that included a 
pharmacist in the team reported significant decrease in costs incurred when compared to 
model that didn't have a pharmacist.  The Kaiser model where pharmacists reviewed 
drugs and provided patient education reported a 21.9 percent reduction in direct medical 
costs. The State model where the pharmacist only provided prescription counseling had a  
9.9 percent decrease in costs as compared to the control model (Gerber et al.  1998). 
A 2002 retrospective cohort study that compared the control of blood glucose 
levels in patients with Type 1 and Type-2 diabetes in a clinic that was physician-
supervised but managed by a pharmacist, to patients that received standard physician care 
in the same clinic. The study reported that the risk having an A1C level (value measuring 
the level of blood sugar in blood over the last the months) of at least seven percent was 
significantly greater in the group that only received physician care as opposed to the 
group that received both pharmacist as well as physician care (Irons 2002).  The 
physician-managed group also had a higher number of diabetes-related clinic visits per 
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patient per year leading the authors to conclude that pharmacist-managed diabetes care 
had been effective in improving patient outcomes in diabetes patients by improving 
glycemic control without causing an increase in the number of clinic visits (Irons 2002).   
A 2013 prospective, multi-center cohort study by Farland and colleagues assessed 
the effect of providing patient care to diabetes patients under a pharmacist-physician 
collaborative agreement.  The study was based in seven practice sites in Tennessee and 
measured the level of glycemic control that was achieved by Type 2 Diabetes patients 
who were provided care under the collaborative agreement. (Farland et al., 2013).  The 
terms of the collaborative agreement were fixed prior to the commencement of the study. 
The study included patients who were over 18 years old and had a life expectancy that 
was more than one year.  These patients were followed for twelve months (Farland et al., 
2013).  Primary outcomes assessed in two hundred and six mostly male patients 
averaging sixty years of age included hemoglobin A1C (A1C is a value measuring the 
level of blood sugar in blood over the last the months), number of patients who had A1C 
levels that were lower  than seven percent and the number of patients that had A1C levels 
which were greater than nine percent.  The study reported a reduction of around one 
percent in A1C levels while the percentage of patients whose A1C levels were lower  
than seven percent increased from 12.75 percent at the beginning of the study to 36.76 
percent at the end of the twelve month follow-up period  The study concluded that 
involving pharmacist in collaborative care for diabetes patients without increasing the 
medications had a positive effect on improving blood glucose control and diabetes 
control without any corresponding increase in self-reported hypoglycemic events 
(Farland et al., 2013).  
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Similar results were seen in a study that evaluated the impact of pharmacist 
management of patients with diabetes mellitus enrolled in a new pharmacist service at a 
rural free clinic (Sease, Franklin, & Gerrald, 2013).  The study included ninety-five 
patients over eighteen years of age who qualified for free care and had a diagnosis of 
Type-2 diabetes.  Study participants were given diabetes education, lifestyle modification 
counseling and managed drug therapy under a collaborative practice agreement between 
physicians and pharmacists.  The study was conducted over twenty-four months. The 
outcomes assessed were changes in A1C levels, blood pressure levels and lipid levels 
(Sease et al., 2013).  The study also reported that significant reductions in Hemoglobin 
A1C values,  blood pressure levels (both systolic and  diastolic) LDL cholesterol levels, 
as well as triglyceride levels were seen in patients who received care under CDTM, when 
compared with their original values at the beginning of the study period (Sease et al., 
2013).  Using cost estimates from literature that reported expected savings of $1,118 per 
patient for those patients that showed more than a one percent lowering of A1C values,  
the pharmacist service was estimated to provide savings to the tune of  seventy five 
thousand dollars in one year. 
Patients in six were provided care under Physician-Pharmacist CDTM for blood 
pressure control.  The blood pressure levels of these patients after 24 hours of receiving 
treatment were compared (Chen, Ernst, Ardery, Xu, & Carter, 2013).  The six clinics in 
the study were randomly assigned to two groups based on whether they were under 
CDTM care (three clinics, hundred and seventy-six patients) or under a physician only 
(three clinics, hundred and ninety-eight patients) (Chen, Ernst, Ardery, Xu, & Carter, 
2013).  The authors reported significantly lower mean blood pressure levels in the 
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pharmacist-physician managed group.  According to the study, collaboration between 
physicians and pharmacists also resulted in an increase in the use of antihypertensive 
drug therapy for patients in the group provided with care under CDTM as compared with 
the group that received usual care  (Chen et al., 2013).   
A series of studies based in North Carolina, known as the Asheville project, 
showed significant improvement in outcomes when community pharmacists trained in 
diabetes care began participating in collaborative care (Cranor et al.  2003).  This was 
demonstrated via a longitudinal study based in twelve community pharmacies in 
Asheville, N.C.. This pre-post cohort study assessed the effects of adding a community 
pharmacist that had received diabetes treatment certification and was getting reimbursed 
for providing Pharmacist Collaborative Services to the health care management team for 
patients with diabetes (Cranor et al.  2003).  Changes in glycosylated hemoglobin (A1C), 
which is the value measuring the level of blood sugar in blood over the last the months, 
were measured.  The study also measured any changes in the cost of treatment for the 
patients as well as utilization of the pharmacist and the physician.  Mean A1C values 
showed a decrease at each of the follow-ups.  The number of patients with that achieved 
target A1C levels also went up in each follow-up (Cranor et al.  2003).  Average direct 
medical costs showed a decrease of twelve hundred dollars for each patient in one year.  
The increases in worker productivity resulting from this were reported to be worth 
$18,000 per year (Cranor et al.  2003). 
 Prior studies in literature have reported an improvement in patient outcomes 
when anticoagulation therapy is managed by a trained and experienced pharmacist as 
opposed to when anticoagulation therapy is provided by physicians in the standard way. 
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(Young et al.  2011; Stafford et al.  2011).  A 2006 retrospective cohort study by Young 
and colleagues compared an  anticoagulation program that was managed by a pharmacist 
to a program in which patients received the standard care from physicians.  The study 
was based in a clinic for family medicine. One hundred and twelve patients on warfarin 
in the pharmacist-managed group were compared to eighty-one patients  in the physician 
managed group. The study was conducted over a seventeen month period.  The study 
assessed outcomes in terms of outcomes such as the percentage of time the patients' 
international normalized ratio stayed inside the recommended therapeutic range, the 
percentage of time that the patients' normalized ratio was reported to be within the 
expanded range and  the percentage of time the international normalized ratio was either 
greater than five or less than one point five (Young et al.  2011).  The study reported that 
the percentage of time the patients' international Normalized Ratio was in therapeutic 
range was seventy-three percent  for the  pharmacist managed group and sixty-five 
percent for  the other group that was only getting  physician care.  This was a significant 
increase (Young et al.  2011).  The authors concluded that the study findings proved that 
 patients receiving care from pharmacists achieved significantly better outcomes 
compared to patients receiving physician care only.   
Impact of CDTM on Economic Outcomes 
Several studies have reported evidence that having a pharmacist involved in direct 
patient care activities can decrease costs associated with medication errors.  In 1995, 
Johnson and Bootman estimated that almost sixty percent of the direct costs of drug-
related adverse effects and patient deaths could be saved with pharmacist intervention 
(Johnson and Bootman.  1995).  Pharmacists collaborating with providers in the long-
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term care setting have been reported to be effective in preventing medication errors 
(Grissinger, 2003; Giberson et al.  2011), and hence could contribute towards reducing 
the costs associated with medication problems which has been estimated to be 3.5 billion 
dollars (National Academies Press; 2007:124-25).  Studies that focused on the US 
Department of Veteran affairs have reported that for every dollar that is used for adding a 
clinical pharmacist to the health care management team, the benefit accrued in greater 
than four dollars (Manolakis et al.  2009).  Patel et al. extrapolated average salary data for 
pharmacists and projected $368,000 savings benefit from providing clinical pharmacy 
services for each clinical pharmacist.  (Patel RJ et al.  1999) .  Six hundred 
recommendations to physicians by pharmacists in hospital settings were studied and it 
was reported that around ninety percent of the recommendations were accepted by 
physicians leading to better health outcomes in about a third of the patients in each 
setting.  The mean cost avoidance for all the recommendations was calculated to be  
seven hundred dollars each resulting in savings to the tune of four hundred thousand 
dollars (Lee et al.  2002).  The Asheville project that assessed the economic impact of 
providing CDTM based drug therapy management to patients with Asthma found that 
savings in direct costs that resulted from providing collaborative care to pharmacists were  
approximately  seven hundred and twenty five dollars per patient for each year, while 
indirect medical costs reduced by around twelve hundred dollars per patient per year 
(Cranor et al.  2003).   
The 2013 study by Sease and colleagues that assessed the impact of providing  
pharmacist managed patient care to ninety-five patients with Type-2 diabetes at a free 
rural clinic also used published cost estimates to calculate the economic impact  of the 
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collaborative practice intervention in terms of  expected savings for each patient who had 
a decrease of more than one percent in HbA(1c) value (Sease et al., 2013).  The study 
reported that the addition of physician-pharmacist collaborative service resulted in 
savings estimated at $74,906 per year.  This figure was calculated using an expected 
savings rate of $1,118 per patient who had a decrease of more than 1 percent in HbA(1c) 
value (Sease et al., 2013). 
Perceptions of CDTM 
Pharmacists 
Scheerder conducted a survey of two hundred community pharmacists and 
reported that pharmacists are more satisfied with their professional activities when they 
are involved in patient-centered services as opposed to product-oriented activities 
(Scheerder 2008).  Pharmacists were found to generally have a very positive attitude 
towards participating in depression care (Scheerder 2008).   
Pharmacy directors surveyed in 2003 demonstrated a positive attitude towards 
CDTM, specifically in terms of the support they felt CDTM had from health care 
providers and hospital administrators (Thomas et al.  2006).  They expressed that they felt 
that the impact of CDTM was strategic, not financial, with directors in hospitals with 
CDTM placing greater value on the strategic impact of CDTM compared to directors in 
hospitals without CDTM.  They also viewed CDTM as being strategic in terms of 
increasing the value of pharmacists for upper administration (Thomas et al.  2006).   
A 2013 study assessing physician and pharmacist views on collaborative practice 
used two separate questionnaires that were sent out to community pharmacists and family 
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physicians.  Both surveys contained questions on attitudes towards CDTM , respondents' 
past experience with CDTM, perceptions of  pharmacist contribution to CDTM, 
disease/treatment areas in which collaborative practice could be expanded and barriers to 
the adoption of CDTM (Kelly et al., 2013)  The survey had a very high response rate of 
over  seventy-six percent from pharmacists and it reported that pharmacists main 
expectations from CDTM was the opportunity to be able to  identify and treat any 
problems patients face due to drug therapy.  This differed from the physician response to 
the survey.  Physicians as well as community pharmacists surveyed in the study were of 
the opinion that CDTM could greatly improve patient outcomes.  Both groups also felt 
that the major barriers to the implementation of collaborative practice agreements were 
shortage of time, lack of compensation, and the problems associated with having to  work 
with multiple pharmacists or physicians (Kelly et al., 2013). 
A 2008 study by Murawski and colleagues assessed pharmacist perceptions of 
CDTM in the states of New Mexico and North Carolina (Murawski et al., 2011).  The 
survey was answered by 189 certified pharmacist clinicians, a majority of whom were 
based in community or institutional settings, most often hospital clinics or physician 
offices.  It was reported that over ninety percent of the respondents surveyed indicated 
that patients were “a great deal” satisfied with services provided by advanced-practice 
pharmacists and around eighty-five of the respondents felt that physicians were “a great 
deal” satisfied with their services.  Half of the respondents were of the opinion that their 
organization’s administration was “a great deal” satisfied with their services.  
Pharmacists also believed their services to be providing economic benefit to the patients 
(eighty-three percent of the respondents felt they were saving money for their patients), 
16 
 
while over ninety percent of the participants felt that they were decreasing costs for the 
government (Murawski et al., 2011).  Around eighty percent of the pharmacists believed 
that their services had resulted in "a great deal" of improvement to patient outcomes.  
However, in spite of the general view that CDTM was improved patient outcomes, 
around thirty-eight percent of the pharmacists surveyed said they were required to justify 
the implementation of collaborative practice (Murawski et al., 2011).   
Physicians 
Studies focused on physician attitudes towards CDTM have yielded contradictory 
results.  In 2009, A mail survey was carried out for a random sample of five hundred 
physicians based in West Virginia.  The survey used included questions on the  
physicians' opinions about the activities performed by pharmacists, the level to which 
they were comfortable with pharmacists providing certain Medication Therapy 
Management (MTM) services, and their general attitudes towards a CDTM agreement 
with pharmacists.  More than half of the sample had a positive attitude toward CDTM. 
However they had a more negative outlook on the pharmacists' role in CDTM and 
Medication Therapy Management (MTM).  Most physicians surveyed reported being 
comfortable only with letting pharmacists perform specific activities Medication Therapy 
Management (MTM) services.  These activities included providing patients with drug 
education, and identification of medication errors (Alkhateeb et al.  2009).  On the other 
hand, Airmet et al. reported that physicians tend to have consistently more negative views 
about pharmacists providing clinical pharmacy services, providing pharmaceutical care, 




A 2013 study assessing physician and pharmacist views on collaborative practice 
used two separate questionnaires that were sent out to community pharmacists and family 
physicians.  Both surveys contained questions on attitudes towards CDTM , respondents' 
past experience with CDTM, perceptions of  pharmacist contribution to CDTM, 
disease/treatment areas in which collaborative practice could be expanded and barriers to 
the adoption of CDTM (Kelly et al., 2013).  Though the survey had a very low response 
rate from physicians at seven percent, the respondents to the physician survey favored an 
increase in collaboration for insurance approvals, patient counseling, and improved 
patient adherence.  The study results showed disagreement between physicians and 
pharmacists in terms of the disease/treatment areas for care provided under CDTM.  
However the low response rate for the physician survey as opposed to the pharmacist 
survey makes it difficult to generalize these findings to all physicians.  (Kelly et al., 
2013) 
A study in 2011 study compared the effectiveness of providing care under 
CDTM, where pharmacists, under the supervision of a physician, ordered laboratory tests 
and changed drug strength, to providing only physician care the for patients taking lipid-
lowering medication (Lalonde et al., 2011).  The study also assessed the opinions of 
physicians, pharmacists, and patients regarding the collaboration as well as the kind of 
care provided.  The authors stated that physicians were of the opinion that collaborating 
with pharmacists was necessary due to shortage of physicians.  However they claimed to 




A cross-sectional study of Michigan office-based physicians conducted by 
Kucukarslan and colleagues assessed physician beliefs about CDTM, their general 
attitude towards collaborating with pharmacists, and their plans for establishing 
collaborative agreement with community pharmacists to provide drug therapy to patients 
(Kucukarslan, Lai, Dong, Al-Bassam, & Kim, 2011).  A total of eleven hundred and nine 
physicians were sampled, with the response rate being approximately thirty percent.  The 
findings of the study indicated that physicians’ were of the opinion that providing patient 
care under a collaborative agreement with a community pharmacist would improve 
medication adherence in patients that received this care.  The study found that physicians 
who believed that collaborative practice would improve patient outcomes were more 
likely to participate in CDTM.  According to the study results,  physician beliefs and 
attitudes toward collaborative practice was associated with their  decision to participate in 
collaborative care (Kucukarslan et al., 2011).   
Patients 
Patients with dyslipidemia who were enrolled in a study by Lalonde and 
colleagues were found to be highly appreciative of the pharmacist contribution to their 
health care team (Lalonde et al., 2011).  Most patients in the study reported feeling that 
satisfied with the follow-ups that were conducted.  Patients also reported that the re-
assurance and information received from pharmacists during follow-up had increased 
their desire to take better care of themselves.  The patients gave maximum credit to the 
pharmacists' communication skills as well as ease of access for their positive feelings 
towards their health care management (Lalonde et al. 2011).   
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Patients in the diabetes portion of the Asheville Project were surveyed at baseline 
as well as eight and fourteen months after enrollment about their satisfaction with 
pharmaceutical care services (Cranor et al.  2003).  Patients were asked to rate their 
satisfaction with the pharmacists, the pharmacists' explanation of drug therapy, the 
pharmacists' technical competence, and the courteousness of the staff.  Satisfaction scores 
were seen to improve during the study, indicating that the patients were more satisfied 
with the quality of care that was provided from when CDTM was incorporated into their 
care. 
Facilitators of CDTM 
There has been limited research focused on identifying facilitators of 
collaborative drug therapy management, however a 2003 survey of pharmacy directors 
identified physician and other medical staff support, advanced education and training of 
pharmacists, upper administration support, and pharmacists’ desire to participate in 
CDTM as the most salient facilitators of CDTM (Thomas et al. 2003).   
In 2008, Murawski and colleagues surveyed 189 pharmacist clinicians and 
pharmacist practitioners in North Carolina and Mexico to assess their views on practice 
sites for CDTM, reimbursement issues and  types of protocols used for collaborative 
practice (Murawski et al. 2011).  The survey had a response rate of thirty-four percent 
with the majority of survey participants practicing in community or institutional settings, 
most often hospital clinics or physician offices.  The respondents to the survey were 
asked to identify which factors they felt were most responsible for successful program 
implementation at their institutions.  Key factors in program success cited by survey 
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participants in decreasing order of importance were provider support and “buy-in”, 
reporting of health outcomes data,  the reporting of financial metrics, patient acceptance 
and buy-in administrative support, proper workload balance, a demonstrated need for 
services, the personal drive of the pharmacist, cost neutrality for the institution, training 
and certification, a manageable number of targeted disease states and a balanced patient 
caseload (Murawski et al., 2011). 
 
Barriers To CDTM 
A lack of education in mental health issues was identified as the main barrier to 
pharmacists providing collaborative care to patients with depression by over seventy-five 
percent of pharmacists surveyed (Scheerder 2008).  Other frequently reported barriers 
were shortage of time to spend with patients, insufficient patient and treatment 
information, difficulty finding a private setting in the pharmacy to conduct patient 
interviews as well as problems with talking to patients with depression (Scheerder 2008). 
A 2013 study by Kelly and colleagues stated that both physicians and pharmacists 
surveyed by the study chose the lack of time and compensation for collaborative 
activities as well as the difficulty caused by needing to work with multiple pharmacists 
and physicians as the main barriers to widespread adoption of CDTM (Kelly et al. 2003). 
A major hurdle to the adoption of CDTM practices in general has been perceived 
to be "turf wars" between physicians and pharmacists (Airmet 2001 ; Murawski 2011; 
Thomas 2003).  In 2001, Airmet and Adamcik reported that physicians consistently had 
more negative views about pharmacists providing clinical pharmacy services, providing 
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pharmaceutical care, and engaging in collaborative drug practice agreements than did 
pharmacists (Airmet et al.  2001).  In 2003, Thomas et al. conducted a survey of a 
pharmacy directors which asked them to identify what they perceived to be the major 
barriers to CDTM.  As per the study findings, insufficient number of pharmacists and less 
support from physicians and medical staff were the most commonly cited barriers 
(Thomas et al.  2003).   
The 2008 survey of pharmacists in North Carolina and New Mexico assessed the 
main implementation barriers to CDTM as identified by pharmacists (Murawski et al., 
2011).  Some major barriers identified were issues with acceptance, reimbursement 
challenges, administrative issues, patient acceptance and awareness, lack of previous 
program experience, legislation or regulations, cost issues, space issues and time 
constraints (Murawski et al., 2011).  Further pitfalls to avoid while implementing a 
collaborative practice were identified to be inadequate planning, poor choice of disease 
concentration, “turf wars,” improper billing methods, performance of extra duties as a 
part of normal pharmacy practice, supervisors’ lack of clinical experience, financial 
problems, and failure to use the facility’s electronic medical record (Murawski et al., 
2011). 
Extent of Pharmacist Practice 
Forty-eight states have passed legislation permitting some form of collaborative 
practice, meaning that each state has  individual state pharmacy laws that allow 
pharmacists to “initiate, modify, and/or discontinue drug therapy pursuant to a 
collaborative practice agreement or protocol” (Giberson et al.  2011).  Some states 
22 
 
specifically address CDTM in their state practice acts while others do not (Giberson et al.  
2011).  According to the American Pharmacists Association, the services provided by 
pharmacists across the country has been increasing  in scope via CDTM agreements 
between pharmacists and other health care professionals (Weaver 2013).  These 
agreements signify a formal partnership between pharmacists and health care 
professionals who are mostly physicians, and permit drug therapy management to take 
place in a collaborative setting (Weaver 2013).  
As per a report published by the APhA (American Pharmaceutical Association) 
and the National Alliance of State Pharmacy Associations (NASPA), as of 2013, 47 
states and the District of Columbia allow for CDTM, including the state of Tennessee 
which allows for physician-pharmacist collaboration in spite of not having a collaborative 
practice agreement (CPA) provision in the state law (Weaver 2013).  
The scope and extent of the pharmacist services, including any limitations on 
practice sites and disease/treatment categories, ability to order laboratory test and 
eligibility requirements for pharmacist participation, differs greatly even among states 
with  collaborative practice agreement provisions (Weaver 2013; Giberson et al.  2011).  
Krystalyn Weaver of the American Pharmaceutical Association (APhA) foundation 
reported on findings from a new analysis by the APhA and the National Association of 
Specialty Pharmacy regarding current Collaborative Practice Agreement legislation 
across the country that state that in 2013 thirty-three states plus the District of Columbia 
allowed pharmacists to participate in initiating drug therapy (Weaver, 2013).  Weaver 
states that eight states exclude community pharmacies from the practice sites that have 
collaborative practice authority, thirty-one states allow ordering and interpretation of 
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laboratory tests, six states mention only specific disease states that can be included in the 
collaborative practice agreement, and "many more" have legislation that makes it 
mandatory for the agreement to be disease-state specific for each patient (Weaver, 2013).  
The report also states that "many" states allow pharmacists to discontinue drug therapy 
while "nearly all" the states with collaborative practice agreement provision allowed 
pharmacists to modify drug therapy, but the actual figures for both these services were 
not forthcoming  (Weaver, 2013).   
In 2003, Thomas et al. conducted a comprehensive survey to gauge the extent and 
scope of collaborative drug therapy management (CDTM) in U.S.  hospitals as well as 
assess pharmacy directors' opinions regarding the effects of CDTM, regulations affecting 
CDTM and financial impact of CDTM (Thomas et al. 2006).  It was reported that 
approximately half of the respondent hospitals had some pharmacists engaged in 
collaborative practice.  Most respondent hospitals that had any kind of CDTM had 
pharmacists involved in ordering laboratory tests (84.2 percent), adjusting  a drug's 
strength (86.7 percent), and changing a drug's frequency of administration (81.6 percent).  
Only 12.7 percent of hospitals with CDTM reported charging a fee for the CDTM 
services provided.  
In 2008, Murawski and colleagues surveyed 189 pharmacist clinicians and 
clinical pharmacist practitioners in North Carolina and Mexico to elicit information 
on practice settings, billing and reimbursement methods, collaborative drug therapy 
management (CDTM) protocols, and other issues (Murawski et al., 2011).  The survey 
had a response rate of 34 percent, with the majority of survey participants practicing in 
community or institutional settings, most often hospital clinics or physician offices.  At 
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the time of the survey, about eighty percent of the respondents were found to be engaged 
in a CDTM protocol.  The study also asked the respondents to identify specific activities 
they were participating in as covered under the protocol.  Of the 189 respondents, 21 
pharmacists (32.8%) reported having prescribing authority; while eight respondents 
(12.5%) indicated that they had the ability to order laboratory tests and other procedures 
to help manage patients.  Around seven percent of the respondents indicated that the 
governing protocol at their institution was specific to a particular disease state with 5.5 
percent of the patients  indicating that protocol-specified guidelines followed the North 
Carolina Board of Pharmacy guidelines and 1.6 percent reporting that the protocol 
required them to document all patient encounters (Murawski et al. 2011).   
The main disease states where the pharmacists were involved in some kind of 
collaborative practice were identified by the respondents to be diabetes (approximately 
sixty percent), coagulation or lipid disorders (approximately fifty-five percent), 
hypertension ( approximately forty-seven percent), chronic obstructive pulmonary 
disease (COPD) (approximately twenty-three percent), pain (approximately twenty 
percent), and heart failure (less than twenty percent) (Murawski et al. 2011).   
The 2012 national American Society of Health-System Pharmacists survey of 
pharmacy practice in U.S.  hospital settings was a mail survey that was conducted for a 
stratified random sample of pharmacy directors at approximately fifteen hundred general 
hospitals  and children's hospitals  (Pedersen, Schneider, & Scheckelhoff, 2013).  The 
survey reported a response rate of 34 percent.  It was seen that the rate 
of pharmacist monitoring of approximately 75 percent of the patients in the hospitals 
surveyed had more than doubled from 2000 to 2012.  It was further reported that 
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collaborative drug therapy management programs were present at most hospitals with 
pharmacists at more than 80 percent of the hospitals participating in the ordering of  
laboratory tests and adjusting drug strength.  Pharmacists routinely performed discharge 
counseling in around a fourth of the hospitals that responded to the survey (Pedersen et 
al., 2013). 
Objectives 
The overall objective of the project was to study the extent and scope of 
collaborative drug therapy management (CDTM) in U.S. hospitals as well as pharmacy 
directors’ perceptions regarding CDTM.  The specific objectives of this study were to 
1)  Assess the current extent, scope and perceptions of CDTM in U.S.  hospitals, 
 2) Determine the associations between hospital characteristics, pharmacy director 
characteristics, and perceptions of CDTM 
3) Investigate hospitals' short-term and long-term plans regarding CDTM 
4) Identify pharmacy directors' views about the major facilitators and barriers for 
CDTM in hospitals. 
Project Significance 
The scope of Pharmacy Practice has expanded over the last ten years (Giberson et 
al.  2011 ; Taylor 2008).  A report to the US Surgeon General in 2009 states that after a 
patient has received a confirmed diagnosis, the patient health care team generally 
includes several pharmacists that help the patient to manage their disease and also deliver 
patent care services as health care providers in the United States (Giberson et al.  2011).  
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However, according to George Halvorson, chairman and CEO of the Kaiser Foundation 
Health Plan, Inc. clinical pharmacists are still "the most underutilized members of the 
health care team” (Giberson et al.  2011). 
Data are limited regarding the actual number of pharmacists who are engaging in 
CDTM and the kind of services they provide, with prior literature primarily focusing on 
the legal ability of pharmacists to participate in CDTM without looking at empirical 
evidence to see the actual practices being implemented in health care settings.  There is a 
need for current data on the extent to which CDTM is being implemented in hospitals. 
 Measures have been taken to address the barriers to CDTM, as have been 
identified previously, with pharmacy education engaging in widespread curricular change 
to better prepare graduates to assume increased responsibility for patient care.  The 
minimum required qualification for a pharmacist has been has been elevated from a BS in 
Pharmacy to a Doctor of Pharmacy (Giberson et al.  2011).  The number of years required 
to obtain a Doctor of Pharmacy degree has also gone up over the years, from the original 
four years to a minimum of six years, which is the current requirement.  Giberson states 
that the time invested in getting a Doctor of Pharmacy degree and the intensity of the 
program is at par with the education received at dental school and is ahead of the kind of 
training received by most other health care providers (barring physicians) (Giberson et al.  
2011). 
Respondents to a survey in a 2001 study by Airmet and colleagues focusing on 
pharmacist and physician views of collaborative practice chose "turf wars" between 
physicians and pharmacists as the main barrier to the adoption of collaborative practice 
(Airmet et al.  2001).  However there have been several recent studies that report contrary 
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findings.  Of these, the 2008 respondent-driven survey Clinical Pharmacy Specialist 
(NCPS) Program within the U.S.  Public Health Service, which was answered by 117 
physicians representing 13 states, presented the most decisive findings in favor of 
physician-pharmacist collaboration.  All the data was sourced from facilities that practice 
CDTM and in 87.2 percent of the cases, the physician had worked or was currently 
working with a NCPS recognized pharmacist.  Ninety-six percent of physicians surveyed 
reported some benefits, including an improvement in health outcomes, increased 
productivity, more time to focus on complex and critical cases instead of chronic disease 
patient and  improved access to access to care for patients. Eighty-eight percent of the 
surveyed physicians felt that including pharmacists in the collaborative practice had 
improved primary care (Giberson et al. 2011).  So there is evidence of a change in trend 
regarding physician attitude towards CDTM which would merit further investigation.  
However there is still need to investigate the nature of this collaboration as is currently 
being practiced, as there is a dearth of literature in this regard. This project seeks to serve 
that need. 
To summarize the findings from the previous paragraph, there seems to have been 
a substantial change in the practice as far as evidence regarding physician approval of 
pharmacist collaboration is concerned (Giberson et al. 2011).  There has also been steady 
growth in the number of state laws and regulations enabling pharmacists to engage in 
CDTM.  In 1996, Shefcheck and Thomas reported that 16 states had laws authorizing 
pharmacists to initiate and modify drug therapy in concert with prescribers, and 16 other 
states were pursuing such laws (Shefcheck and Thomas, 1996).  Twenty-one states had 
pharmacist CDTM laws by 1998 (Ferrko et al.  1998), which increased to 32 states in 
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2003 (Punekar et al.  2003).  As of 2012, 47 states allowed some form of collaborative 
practice (Giberson et al.  2011).  However, little data is available on the extent and scope 
of CDTM occurring in U.S.  hospitals.  Assessing the current opinions of pharmacy 
directors on various aspects of CDTM can help the pharmacy profession identify factors 
that act as potential barriers or facilitators to the growth of CDTM.   
In this study, we explored the extent and scope of collaborative drug therapy 
management (CDTM) in U.S.  hospitals and also identify pharmacy directors' perceptions 
regarding CDTM.  There is little data available on the extent to which CDTM is being 
implemented in U.S.  hospitals.  Also, assessing the current opinions of pharmacy 
directors on various aspects of CDTM can help the pharmacy profession identify factors 
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Study Design and Setting  
A cross sectional research design, utilizing a self-administered written survey was 
adopted to address the study objectives, which were to assess the extent and scope of 
CDTM in U.S. hospitals and identify pharmacy directors' opinions on CDTM.  The 
survey questionnaire was administered to a random national sample of hospital pharmacy 
directors.  A written study protocol was submitted to the Purdue University IRB center 
for approval before the initiation of the research.   
The Survey Instrument 
A mail survey developed and validated by Thomas et al.  (Thomas et al.  
2003) was used to collect data.  The mail survey asked respondents to indicate 
whether any pharmacists in their hospital are engaged in CDTM or collaborative 
practice that involves the initiation or modification of drug therapy.  It contained 
questions on the respondents' views about CDTM, the extent and scope of CDTM 
activities in their institution, their long and short term plans involving CDTM, as 
well as demographic data on the pharmacy directors and hospital characteristics.  
The survey also had two additional open-ended questions that asked the 
respondents what they perceived to be the greatest
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barrier to CDTM as well as the greatest facilitator of CDTM. The survey used in the 
study is included in Appendix A. 
The survey also contained twenty-seven items assessing respondents’ opinions 
about the range and scope of practice in CDTM (six items), the support for CDTM by 
other health care providers and administrators in the hospital (nine items), the strategic 
value provided by collaborative practice to the pharmacy (three items), any financial 
value created by collaborative practice (five items), and nature of current state regulations 
that affect collaborative practice (four items).  These twenty-seven items were further 
summed to form four scales: the support for CDTM scale (eight items), the strategic 
impact of CDTM scale (three items), the financial impact of CDTM scale (four items), 
and the regulations affecting CDTM scale (four items).  The support for CDTM scale 
assesses pharmacy director perceptions about the support for CDTM activities from the 
hospital staff, including medical staff and upper administration (Thomas et al. 2003).  
The strategic impact of CDTM scale measured how collaborative practice has affected 
upper administration's perception of pharmacists and facilitated implementation of 
CDTM (Thomas et al. 2003).  The financial impact of CDTM sub-scale measured 
perceived financial effects of collaborative practice, including reimbursement issues 
(Thomas et al. 2003), while the regulations affecting CDTM assessed pharmacy director 
perceptions of the range and scope of current regulations regarding CDTM.  Respondents 
indicated their degree of agreement with each statement on a five-point Likert scale.  
Items regarding perceptions on CDTM that were negatively worded were reversed scored 
for analysis and scale scoring.  Item ratings for each scale, namely the support for CDTM 
scale, the strategic impact of CDTM scale the financial impact of CDTM scale, and the 
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regulations affecting CDTM scale, are added to give a scale score. Each scale 
score is then divided by the number of items in the scale to obtain a score ranging 
from one to five.  Scores close to one indicate strong disagreement and scores 
close to five indicate strong agreement with the perception.  
The survey being used in this study was developed and validated in a 
previous study by Thomas and colleagues in 2003 (Thomas et al. 2003).  To 
validate the survey, Thomas and colleagues evaluated the psychometric properties 
of the scales measuring respondents’ opinions about CDTM.  All items in each of 
the four scales, namely, the support for CDTM scale, the strategic impact of 
CDTM scale, the financial impact of CDTM scale, and the regulation affecting 
CDTM scale, were reported to have Cronbach's alpha's values that were greater 
than 0.7.  Therefore the scale items were said to have good internal consistency.  
(Thomas et al. 2003). 
Sample Size Determination 
 A stratified random sample of one thousand and twenty-six hospital pharmacies 
was selected from the hospital executives mailing list received from F1RSTMARK 
Hospital Executives.  The mailing list included contact information for U.S. hospitals 
across the country which had Pharmacy Director information available. The estimated 
sample size was based on the binomial distribution, which generated a required sample of 
three hundred and twenty-one surveys to estimate the percentage of hospitals having 
CDTM when the error was within plus or minus five percentage points at a confidence 
interval of ninety-five percent.  The probability of a hospital having CDTM was taken to 
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be 0.3.  A response rate of approximately thirty percent was assumed.  Dividing the 
required sample size by the expected response rate, nine hundred and sixty-three was 
calculated to be the number of surveys required to be mailed.  One thousand and twenty 
six was chosen as the sample size to allow some  margin for undeliverable 
questionnaires. 
Sample Selection 
The sample of hospitals was obtained from the hospital executives mailing list 
received from F1RSTMARK Hospital Executives.  The mailing list included contact 
information for hospitals across the country for which Pharmacy Director information 
was available. Stratified sampling was used to determine the sample size for each state.  
The number of hospital pharmacies in fifty states was obtained from the guide.  The 
number of pharmacies in each state was divided by the total number of pharmacies to 
obtain a sampling fraction or ratio for each state. Each fraction was multiplied by 1,026, 
the calculated sample size, to obtain the sample size for each state ( appendix F).   
Data Collection 
The survey strategy was based on the Dillman method for mailed surveys (Table 
1)  that has been reported  to improve response rate (Dillman, 2007).  To maximize 
response rate, Dillman recommends that all prospective subjects be sent a personalized 
advance-notice letter informing them about the survey and the questionnaire they would 
be receiving shortly.  Approximately one week later, a complete survey package with a 
cover letter, instructions, the questionnaire and including a return envelope with postage, 
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should be sent to the participants.  A follow-up postcard that includes a thank you note as 
well as a reminder should be mailed out a week after that.  Two weeks after mailing the 
follow-up postcards, a new cover letter, questionnaire, and return postcard is to be sent to 
those who have not, possibly by registered post,  to request completion of the survey.   
Advance notice letters informing the selected pharmacy directors about the survey 
they would be soon receiving were sent by first class mail on September 9, 2013. The 
script for the letter is included in Appendix B.  Following the mailing of the advance 
notice letters, the questionnaires and cover letters for the first round of data collection 
were sent by first class mail on September 16, 2013 with "pre-paid postage" business 
reply covers.  The questionnaire is included in Appendix A, while the cover letter used 
for the first round of data collection is included in Appendix C.  The questionnaires were 
also numbered to keep track of receipts in order to eliminate follow up mailings to 
respondents that had already returned their questionnaires. As per schedule, a reminder 
cum thank you post card was sent to all the pharmacy directors in the original sample on 
September 23, 2013, a week after the first mailing of the surveys.  The script for the 
follow-up post card can be found in Appendix D. 
Two weeks after the first mailing, a hundred and twenty six questionnaires had 
been received and another eighty-four had been returned undelivered.  The letters were 
returned if the pharmacy director could not be reached.  The first follow-up survey 
package was mailed on October 7, 2013.  
A second follow-up consisting of another copy of the questionnaire and a cover letter was 





Table 1. Survey Mailing Schedule Based on Dillman Method for Mail Survey 
 
  __________________________________________________________________  
Week Task 
 ___________________________________________________________________  
Week 1 Mailed out personalized advance notice letters to  
  prospective subjects informing them about the  
  survey they will be receiving shortly 
 
Week 2 Mailed a survey package containing a cover letter,  
  instructions, the questionnaire and a return envelope 
  with postage to the subjects 
 
Week 3 Mailed a follow-up postcard that includes a thank  
  you note as well as a reminder to all subjects 
 
Week 5 Two weeks after mailing the follow-up postcards,  
  mailed the survey along with a new cover letter and  
  return postcard to the subjects who were yet to  
  respond, requesting them to complete the survey 





to change of pharmacy director or wrong address were re-addressed and re-mailed. At the 
end of the mailing cycle, a total of eighty-four questionnaires were still returned as 
undeliverable. A total of two hundred and ninety-five surveys were returned by the 
respondents and two hundred and eighty-three of these were considered usable. The net 
usable response rate was therefore calculated to be 30.1 percent.  
Each respondent had a unique number assigned to them which was used to record 
survey data in lieu of personal information.  This ensured that respondent confidentiality 
was maintained at all stages.  
Statistical Analysis 
Data management and analysis was be carried out using SAS for UNIX version 
9.3 (SAS Institute, 2012) Cary, NC.  An a priori alpha level of 0.05 was used for all 
analyses. 
Hospital Characteristics 
Frequency statistics were computed for demographic data on hospital 
characteristics, including institution ownership, institution classification, population of 
the city in which the institution was located, number of beds, and total number of patient 
days in the hospital in the past year. 
Pharmacy Director Characteristics 
Frequency statistics were computed for demographic data on pharmacy directors, 
including sex, age, degrees obtained, completion of a residency or receipt of any special 
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certification, and number of years since they had initially obtained a license to practice 
pharmacy. 
Extent and Scope of CDTM in Hospitals 
Based on the responses to the survey, the proportion of hospitals that authorize 
their pharmacists to engage in CDTM was calculated.  The survey asked the respondents 
to list the total number of pharmacists employed at their institution as well as the number 
of pharmacists who are engaged in collaborative practice.  This was used to calculate the 
proportion of pharmacists that are involved in CDTM.  The survey asked pharmacy 
directors to record whether any pharmacist in their hospital is authorized to  perform each 
of the following activities; adjust a drug’s strength, order laboratory or related tests, 
change a drug’s frequency of administration, discontinue a drug, and initiate drug 
therapy, was calculated.  For hospitals that do have pharmacists involved in a particular 
CDTM activity, respondents are asked to further indicate if pharmacists participate in the 
these activity for all patients, or if they are authorized to carry out the activities for 
certain diseases and patients only. Based on these survey items, the percentage of 
hospitals with at least one pharmacist involved in each of the activities listed above was 
calculated. For hospitals that allowed CDTM for that particular activity, the proportion of 
hospitals that authorized the activity for all patients, as well as the proportion of hospitals 
that only allowed pharmacists to engage in that activity for specific diseases and patients 
were calculated. 
 The survey asked whether hospitals have written protocols for CDTM, the 
number of protocols for each hospital, and also the type of the protocols, i.e., whether the 
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protocols are treatment specific, disease specific or general protocols.  Based on these 
survey items, the means and standard deviations for the number of protocols per hospital 
were calculated.  The proportion of hospitals having written protocols was also 
calculated, as well as the distribution of the different types of protocols across hospitals 
(the number of treatment/disease specific protocols and the number of general protocols). 
 The survey also asked respondents to indicate the diseases and treatments for 
which pharmacists in their hospital engage in collaborative practice that involves 
initiation or modification of drug therapy.  The respondents are asked to indicate the 
particular diseases/treatments for which the hospital authorizes CDTM from a list of 
treatment/disease categories provided in the survey.  For each disease/treatment category, 
the survey also asked respondents to indicate the number of pharmacists in the hospital 
that are actually involved in administering CDTM for that particular category and also to 
indicate whether that category has a written protocol for collaborative practice.  The 
disease/treatment categories included were Anticoagulation, Diabetes, Hypertension, 
Asthma, Emergency contraception, Dyslipidimias, Heart Failure, Infectious disease, 
General medicine, Smoking cessation, Pain management, Parenteral nutrition and 
Immunization.  The respondents are also provided with spaces marked "Other" where 
they can add in any disease or treatment that has not been covered by the rest of the 
categories.  This information was used to calculate the proportion of hospitals that 
authorized CDTM for each disease/treatment area listed, and also the proportion of 
hospitals that had a written protocol for CDTM in that particular disease/treatment area. 
This revealed information about the extent CDTM as is being practiced in the hospitals 
surveyed, in terms of the diseases or treatment areas covered. 
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In order to assess the scope of CDTM for each disease/treatment category, the 
survey allowed respondents to indicate the specific kind of CDTM activity that the 
hospital authorized for each disease category.  This was done by providing nine columns 
for each category that are headed with each type of CDTM activity that the hospital can 
authorize. The activities listed were (1) initiate drug therapy, (2) change duration of a 
drug therapy, (3) adjust a drug’s strength, (4) change a drug’s dosage form, (5) change a 
drug’s frequency of administration, (6) change a drug’s route of administration, (7) hold a 
drug, (8)  discontinue a drug and (9) order laboratory or related tests.  For each 
disease/treatment category the respondent marked the boxes below the activities that the 
hospital authorizes pharmacists to provide for that category.  This was used to calculate 
the proportion of hospitals that authorized any pharmacist to perform each kind of CDTM 
activity for each disease/treatment category listed.  This told us about the scope of CDTM 
in terms of the specific CDTM activities authorized for each disease/treatment category 
listed in the survey.  
Associations between Hospital Characteristics, Pharmacy Director Characteristics,  
and CDTM 
The survey collected demographic information on pharmacy directors in terms of 
their gender, age, educational degrees, any residency completed, time since they were 
first licensed to practice pharmacy and any special certification or recognition they may 
have received in pharmacy.   
Respondents were asked to choose between six levels to indicate their age.  
Information on respondent gender was also collected.  Respondents were asked to 
indicate the number of degrees they had completed by providing them with five options. 
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They were asked to indicate the time since obtaining their license by selecting one of the 
six options provided.  Respondents were also asked to indicate the number and types of 
residencies they had completed, if any. Finally they were asked to indicate whether they 
had received any  special certification or recognition in pharmacy. 
Hospital characteristics that were collected included the type of ownership the 
institution has (Private-non- profit, Private-for- profit, or Government),  the institution 
classification, the population of the city in which the institution is located, the number of 
days in the hospital and the total number of patient-days in the hospital in the preceding 
year.  Respondents selected the institution classification from the five options provided 
that were (1) Short-term general and other special (2) Long-term general and other 
special (3) Psychiatric (Mental health institution) (4) TB and other respiratory diseases 
and (5) Other (the respondents were asked to specify the classification if it wasn't listed).  
The population of the city in which the hospital was located was assessed by having 
respondents select one of the twelve levels provided, while bed size was selected from 
eight levels of bed sizes provided in the survey. The respondents were also asked to 
indicate the number of patient-days in their hospital in the previous year on an  open 
ended question.  
Pharmacy director characteristics and hospital characteristics were compared for 
hospitals with and without CDTM.  Associations between characteristics and CDTM use 
were tested using logistic regression.  This enabled us to see the kind of association 
between the different levels of the variable and CDTM use.  Logistic regression was used 





Pharmacy Directors' Perceptions Regarding CDTM 
The frequency distribution of responses for each of the twenty-seven items 
assessing pharmacist opinions on CDTM item was generated, to get an estimate of the 
"spread" of the data.  This distribution is included in  appendix G.  Means and standard 
deviations were calculated for each of the twenty-seven survey items that dealt with the 
range and scope of practice in CDTM, support for CDTM by other health care providers 
and administrators in the hospital , strategic value provided by collaborative practice to 
the pharmacy, financial value created by collaborative practice and nature of current state 
regulations that affect collaborative practice.  For surveys missing observations for no 
more than two of the twenty-seven items on perceptions regarding CDTM, the mean 
score on an item was entered for missing values.  For surveys missing observations for 
more than two items, none of the responses were used in the analysis of perceptions 
regarding CDTM.  Items regarding perceptions on CDTM that were negatively worded 
were reversed scored for analysis and scale scoring.  The responses were based on a 5-
point Likert-type scale, where 1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 
and 5 = strongly agree.  These items were further summated to form four scales, namely, 
the support for CDTM scale (eight items), the strategic impact of CDTM scale (three 
items), the financial impact of CDTM scale (four items), and the regulation affecting 
CDTM scale (four items).  Ratings on each scale were added and divided by the number 
of items in the scale, to obtain a score ranging from one to five.  Scores close to one 
indicate strong disagreement and scores close to five indicate strong agreement with the 
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opinion on CDTM.  Items in the CDTM scale were scored such that higher scores 
represent more positive impact of CDTM.    
Associations between Hospital Characteristics, Pharmacy Director Characteristics, 
 and CDTM use 
Analysis of Variance was used to determine if there was any difference in 
perceptions between hospitals with and without CDTM.  Mean scores for each of the four 
scales, namely, the support for CDTM scale (eight items), the strategic impact of CDTM 
scale (three items), the financial impact of CDTM scale (four items), and the regulation 
affecting CDTM scale (four items), were compared for hospitals that had CDTM and 
hospitals that did not have pharmacists engaged in CDTM.  
Associations between Hospital Characteristics and  Pharmacy Director  
Perceptions of CDTM   
Analysis of variance was used to determine associations between Pharmacy 
Director Perceptions of CDTM and the demographic characteristics of the hospital.  
Newman-Keuls multiple means comparison tests were used for Post-hoc analysis in case 
of significant ANOVA tests.  Newman-Keuls tests are most frequently used in 
psychology and have more power than Tukey tests.  ANOVA was used to determine 
associations between each of the four perceptions scales, namely, the support for CDTM 
scale (eight items), the strategic impact of CDTM scale (three items), the financial impact 
of CDTM scale (four items), and the regulation affecting CDTM scale (four items), and 
hospital characteristics.  Associations between pharmacy director characteristics and 
perceptions of CDTM were tested for the following characteristics gender, age, degrees 
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obtained, completion of a residency or receipt of any special certification, and number of 
years since they had initially obtained a license to practice pharmacy. 
Associations between Pharmacy Director Characteristics and Pharmacy Director 
Perceptions of CDTM  
Analysis of variance was used to determine associations between Pharmacy 
Director Perceptions of CDTM and the demographic characteristics of the hospital.  
Newman-Keuls multiple means comparison tests were used for Post-hoc analysis in case 
of significant ANOVA tests.  Newman-Keuls tests are most frequently used in 
psychology and have more power than Tukey tests.  ANOVA was used to determine 
associations between hospital characteristics and ratings on each of the four perceptions 
scales, namely, the support for CDTM scale (eight items), the strategic impact of CDTM 
scale (three items), the financial impact of CDTM scale (four items), and the regulation 
affecting CDTM scale (four items).  The hospital characteristics that were tested for 
associations with pharmacy director perceptions of CDTM were institution ownership, 
institution classification, population of the city in which the institution was located, 
number of beds 
Plans Regarding CDTM 
The survey asked all respondents to indicate their short- and long-term plans for 
CDTM on a 5-point Likert-type scale, where 1 = large decrease, 2 = slight decrease, 3 = 
no change, 4 = slight increase, and 5 = large increase. Three items assess the hospitals' 
long term plans for CDTM and three items assess the short term plans for CDTM. The 
survey asked respondents to indicate whether the hospitals has any short term plans 
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within one year to make any changes in the following three categories (1) Number of 
staff pharmacists involved in CP,  (2) Number of CP protocols and (3) Number of 
diseases/ therapies in which pharmacist provide CP. The same questions are repeated for 
long term plans that extend beyond one year.  Each item was rated on the 5 point Likert 
scale previously described, that ranged from large decrease to large increase.  The data on 
the short-term (within one year) and long-term plans (beyond one year) of hospitals for 
changes in various aspects of CDTM was tabulated.  Means and standard deviations were 
calculated for each of the items and the percentage of respondents indicating each 
response was also calculated, both for short term as well as long term plans.  
Facilitators and Barriers for CDTM In Hospitals. 
All respondents were asked in open-ended questions to indicate what they 
perceived to be the greatest barrier to CDTM and the greatest facilitator of CDTM.  
These responses were grouped into common themes and tabulated to show the frequency 
with which a particular barrier or facilitator was mentioned by the respondents.  The 
barriers and facilitators so identified were then ordered by frequency in a table that 
displayed the most commonly identified barriers and facilitators according to their 
prevalence in the survey answers.  Some respondents provided multiple answers to both 





Tests for Response Bias 
To test for potential non-response bias, the first third of respondents were 
compared with the last third of respondents.  Based on ‘the continuum of resistance 
model’ late respondents can be used as a proxy for non-respondents in estimating non-
response bias, while early respondents are indicative of all respondents, hence the 
difference between the two will reflect the non-response bias (Voogt et al.  1998).  Chi-
square tests were used to compare categorical variables for early respondents and late 
respondents and analysis of variance were used to compare continuous variables for early 
and late respondents.  The characteristics of early and late respondents that were 
compared were the proportion of hospitals that engaged in CDTM, perceptions regarding 
CDTM, hospital characteristics, and pharmacy directors' characteristics. 
In addition to comparing early and late respondents, the sample distribution on the 
basis of the number of beds in the hospitals (Bed Size) was compared to the distribution 
of bed sizes of the population.  The purpose of doing this was to determine whether the 
random sample that had been drawn differed significantly from the rest of the population 
in terms of demographic characteristics.  Bed Size was used as the parameter since bed 





The survey along with the cover letters that were to be sent with the surveys to 
each respondent were submitted along with other required documents to the Institutional 
Review Board at Purdue University to seek prior approval for the.  The study proposal 
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Demographic characteristics of the study sample, including both hospital and 
pharmacy director characteristics, are summarized using frequency distributions and 
means and standard deviations where appropriate.  Frequency distributions for institution 
ownership, institution classification, population of the city in which the institution was 
located, number of beds, and total number of patient days in the hospital in the past year 
as well as pharmacy directors‘ sex, age, degrees obtained, completion of a residency or 
receipt of any special certification, and number of years since they had initially obtained 
a license to practice pharmacy were developed to gain understanding of the demographic 
characteristics of the population. 
Hospital Characteristics 
Distribution of Hospitals by Institution Ownership 
The distribution of the respondent hospitals by their institution ownership is 
shown in Table 2.  Of the 283 hospitals surveyed, 198 (72.5 percent) were private, not-
for-profit hospitals, twenty (7.3 percent) were private, for-profit hospitals, while sixteen 
(5.86 percent) were government owned.  Thirty-nine hospitals (14.2 percent) did not fall 
under any of the aforementioned categories.
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Table 2. Distribution of Hospitals by Ownership 
________________________________________________________________________ 
   Cumulative Cumulative 
Ownership Frequency Percent Frequency  Percent  
________________________________________________________________________ 
Missing/Unknown 10 3.53 10 3.53 
Private  198 72.53 198 72.53      
Private (For Profit) 20 7.33 218 79.85    
Government( City, county, state) 16 5.86 234 85.71 








Distribution of Hospitals by Institution Classification 
The distribution of the respondent hospitals by their institution classification is 
shown in Table 3.  Of the 283 hospitals surveyed, 198 (69.96 percent) were of type Short-
Term General, twenty (7.07 percent) were Long Term General, while sixteen (5.65 
percent) were Psychiatric facilities.  Only one hospital specialized in TB and other 
respiratory diseases.   
Distribution of Hospitals by City Population 
Table 4 shows the frequency distribution of the respondent hospitals based on the 
population of the city they are located in.  Two hundred and sixty-eight respondents 
volunteered information on their city population.  Of all respondent hospitals, only eleven 
(3.89 percent) hospitals had less than thousand people in their city, with a total of twenty-
nine (10.8 percent) hospitals located in cities with less than 2,500 people.  Respondent 
hospitals' cities were fairly evenly distributed over the 5,000 to 250,000 people range, 
with the 5,000 to 25,000 bracket having the maximum frequency of respondents ( 83 
hospitals, 29.33 percent).  The maximum concentration of hospitals was in cities with 
5,000 to 250,000 people (183 hospitals, 64.66 percent).  Forty-one hospitals were located 




Table 3. Distribution of Hospitals by Institution Classification 
________________________________________________________________________ 
   Cumulative Cumulative 
Institution Class Frequency Percent Frequency  Percent 
 N=283 
________________________________________________________________________ 
Missing/Unknown 10 3.53 10 3.53 
 
Short-term General and  
other special 198 69.96 208 73.50 
 
Long-term General and 
other special 20 7.07 228 80.57 
 
Psychiatric 16 5.65 244 86.22 
 
TB and other respiratory  
diseases 1 0.37 245 86.59 





Table 4. Distribution of Hospitals by City Population 
________________________________________________________________________ 
City Population Frequency Percent Cumulative Frequency  Cumulative Percent 
 N=283 
________________________________________________________________________ 
Missing/Unknown 15 5.30 15 5.30 
Less than 1,500 11 3.89 26 9.19 
1,500 to 4,999 18 6.36 44 15.55 
5,000 to 24,999 83 29.33 127 44.88 
25,000 to 99,999 65 22.97 192 67.84 
100,000 to 499,999 50 17.67 242 85.51 





Pharmacy Director Characteristics 
Distribution of Pharmacy Directors by Age 
The survey sample distribution by respondent age is shown in Table 5.  Out of 
283 participants, 102 (36.04 percent) were between 55 to 64 years old, sixty-six (23.32 
percent) were between 45 and 54 years and sixty-one (21.55 percent) were between 35 
and 44 years.  Only two people were less than twenty-five years old.   
Distribution of Pharmacy Directors by Gender 
The survey sample distribution by respondent gender is shown in Table 6.  Out of 
283 participants, 158 (55.83 percent) were female, while male respondents comprised the 
remaining 38.52 percent of the sample that provided their gender. 
Distribution of Pharmacy Directors by License time 
Table 7 shows the sample distribution by years since obtaining a license.  The 
majority of the participants, that is 192 respondents or 67.84 percent of all respondents, 
had received their license to practice Pharmacy more than fifteen years prior to the study.  
Out of 283 respondents, 248 (87.63 percent) had had a license for more than five years.  
Only three pharmacy directors had received their license within the last three years.   
Distribution of Pharmacy Directors by Completion of Residency 
The survey sample distribution of pharmacy directors by completion of a 
pharmacy related residency is shown in Table 8.  Most pharmacy directors had not 
completed a residency.  Only forty-seven of 279 (16.61 percent) respondents had a 
residency.  Of these, thirty-three pharmacy directors had completed a General Residency 
58 
 
(11.66 percent of all respondents), as shown in Table 9.  Only thirteen pharmacy directors 
(4.05 percent) had completed a specific residency as seen in Table 10. 
Distribution of Pharmacy Directors by Education 
Tables 11 to 15 show the survey sample distribution of the degrees obtained by 
the  pharmacy directors .  As shown in Table 11, approximately half of the respondents 
had a Doctor of Pharmacy degree.  One hundred and fifty two (53.71 percent) of 
respondents had a Bachelor of Science in Pharmacy degree (Table 12), while nineteen 
(6.71 percent) of the respondents had an M.S.  degree (Table 13).  Only three (1.06 
percent) pharmacy directors had a Ph.D.  degree, as seen in Table 13.   
Extent of CDTM 
Percentage of Hospitals with CDTM 
The percentage of hospitals with CDTM was calculated based on the responses to 
the survey question "Do pharmacists in your hospital engage in collaborative practice that 
involves initiation or modification of drug therapy, i.e., active intervention beyond a 
written consult or general therapeutic interchange protocols?"  Of the 283 responses 
received, 186 respondents indicated "Yes" to the question, which means that sixty-five 
percent of the respondent hospitals had at least some pharmacists engaged in 
Collaborative Drug Therapy Management or CDTM 
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Percentage of Pharmacists engaged in CDTM 
The survey asked respondents to list the number of pharmacists employed at the 
hospitals as well as the number of pharmacists actually involved in CDTM.  A total of 
2308 pharmacists were employed across all the respondent hospitals surveyed.  Of these, 
1548 pharmacists were actively engaged in providing CDTM services to patients.  
Therefore, sixty-six percent of all pharmacists employed by the respondent hospitals were 
participating in CDTM. 
Percentage of Hospitals with Written Protocols 
Respondents were asked to indicate if their hospital had specific written protocols 
for collaborative drug therapy management.  Of the 277 participants who responded to 
this question, 163 (58.8 percent) indicated having written protocols in place at their 
hospital. 
Distribution of Hospitals by Type of Protocol 
Table 16 shows the survey sample distribution of the respondent hospitals by the 
type of written protocol defined for collaborative practice .  One hundred and two (36.04 
percent) hospitals had protocols that were disease or treatment specific, while eighty-one 
(28.62 percent) of the hospitals had protocols that were general for several diseases or 
treatments.  Three (1.8 percent) of hospitals  indicated having protocols that did not fall 
into either of the aforementioned categories.  Hospitals could have protocols of more than 






Table 5. Distribution of Pharmacy Directors by Age 
________________________________________________________________________ 
   Cumulative Cumulative 
Age Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________ 
Missing/Unknown 19 6.71 19 6.71 
Less than 34 years 23 8.13 42 14.84   
35 to 44 years 61 21.55 103 36.40 
45 to 54 years 66 23.32 169 59.72 
55 to 64 years 102 36.04 271 95.76 





Table 6. Distribution of Pharmacy Directors by Gender 
________________________________________________________________________ 
   Cumulative Cumulative 
Age Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________  
Missing/No response 16 5.65 16 5.65 
Male 109 38.52 125 44.17 





Table 7. Distribution of Pharmacy Directors by License Time 
________________________________________________________________________ 
   Cumulative Cumulative 
License Time Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________ 
Missing/Unknown 18 6.36 18 6.36 
1 to 3 years 3 1.06 21 7.42 
3 to 5 years 10 3.53 31 10.95 
5 to 10 years 22 7.77 53 18.73 
10 to 15 years 38 13.43 91 32.16 




Table 8. Distribution of Pharmacy Directors by Completion of Residency  
________________________________________________________________________ 
   Cumulative Cumulative 
Residency Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________ 
Missing/Unknown 4 1.41 4 1.41 
No Residency  232 81.98 236 83.39 
Residency completed 47 16.61 283 100.00 
________________________________________________________________________   
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Table 9. Distribution of Pharmacy Directors by Completion of General Residency  
________________________________________________________________________ 
   Cumulative Cumulative 
Residency Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________ 
No General Residency  186 65.72 186 65.72      
General Residency completed 33 11.66 219 100.00   





Table 10. Distribution of Pharmacy Directors by Completion of Specific Residency  
________________________________________________________________________ 
   Cumulative Cumulative 
Residency Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________ 
No Specific Residency  201 71.02 201 71.02      
Specific Residency completed 13 4.05 214 75.07 
Missing/Unknown 69 24.38 283 100.00  
________________________________________________________________________    
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Table 11. Distribution of Pharmacy directors with a Doctor of Pharmacy degree 
________________________________________________________________________ 
   Cumulative Cumulative 
Degree Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________ 
Missing/Unknown 12 4.24 12 4.24 
No Degree 135 47.70 147 51.94 






Table 12. Distribution of Pharmacy Directors with a BS in Pharmacy Degree 
________________________________________________________________________ 
   Cumulative Cumulative 
Degree Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________ 
Missing/Unknown 15 5.30 15 5.30 
No Degree 116 40.99 131 46.29 






Table 13. Distribution of Pharmacy Directors with an M.S. Degree 
________________________________________________________________________ 
   Cumulative Cumulative 
Degree Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________ 
Missing/Unknown 32 11.31 32 11.31 
No Degree 232 81.98 264 93.29 





Table 14. Distribution of Pharmacy Directors with a Ph.D. degree 
________________________________________________________________________ 
   Cumulative Cumulative 
Degree Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________ 
Missing/Unknown 32 11.31 32 11.31 
No Degree 248 87.63 280 98.94 





Table 15. Distribution of Pharmacy Directors with any Other Degree 
________________________________________________________________________ 
   Cumulative Cumulative 
Degree Frequency Percent Frequency  Percent  
 N=283 
________________________________________________________________________ 
Missing/Unknown 27 9.54 27 9.54 
No Degree 216 76.33 243 85.87 





Table 16. Distribution of Hospitals by Type of Written CDTM Protocol 
________________________________________________________________________ 
Hospitals with Protocol of Type Frequency Percent 
 N=283 
________________________________________________________________________ 
Treatment/Disease specific 102 36.04 
General  81 28.62 





CDTM Activities  
Pharmacists engaged in Collaborative Drug Therapy Management can perform a 
range of activities.  These include initiating drug therapy, adjusting a drug’s strength, 
ordering laboratory or related tests, changing a drug’s frequency of administration and 
discontinuing a drug.  Hospitals may allow pharmacists to perform the specific CDTM 
activities or services for any patient or they can impose restrictions on the scope of the 
activity by only allowing the CDTM activity to be carried out for a specific patient, 
disease or treatment type.   The survey asked respondents to indicate which CDTM 
activities their hospitals permitted pharmacists to perform.  They were further asked to 
indicate if each CDTM activity was permitted for all patients or only for a specific sub-
category of patients.  The responses to the survey items on CDTM activities are 
summarized in this section. 
Proportion of Hospitals that Authorize Pharmacists to  
Initiate Drug Therapy 
Table 17 shows the proportion of hospitals that allow pharmacists to "initiate drug 
therapy" for patients as part of CDTM.  Of the 183 hospitals surveyed that responded yes 
to having some form of CDTM, 46.98 percent of the respondents indicated that 
pharmacists in their facility were authorized to initiate drug therapy for any patients.  
36.29 percent of respondent hospitals only allowed pharmacists to initiate drug therapy 
for certain diseases and drug therapies, while 12.27 percent of the respondent hospitals 





Table 17. Proportion of Hospitals that Authorize Pharmacists to  
Initiate Drug Therapy 
__________________________________________________________________ 
Percentage of Hospitals with CDTM Authorizing Activity 
__________________________________________________   
CDTM Activity For all patients For certain diseases For any patients 
  and therapies only 
__________________________________________________________________ 





Proportion of Hospitals that Authorize Pharmacists to  
Change Duration of Drug Therapy 
The distribution of hospitals that allow pharmacists to "change duration of drug 
therapy" for patients under CDTM is shown in Table 18.  Of the 183 hospitals that had 
CDTM, 42.99 percent of the respondents indicated that pharmacists in their facility were 
authorized to change duration of drug therapy for any patients.  21.58 percent of 
respondent hospitals allowed pharmacists to change duration of drug therapy for certain 
diseases and drug therapies only, while 15.07 percent of the respondent hospitals allowed 
pharmacists to change duration of drug therapy for all patients, regardless of disease or 
treatment category. 
Proportion of Hospitals that Authorize Pharmacists to 
 Adjust a Drug's Strength 
Table 19 shows the proportion of hospitals that allow pharmacists to "adjust a 
drug's strength" for patients as part of CDTM.  81.59 percent of the 183 respondent 
hospitals with CDTM indicated that pharmacists in their facility were authorized to adjust 
a drug's strength for any patients, which makes "adjusting a drug's strength"  the second 
most common CDTM activity being performed by pharmacists at the respondent 
hospitals.  51.35 percent of respondent hospitals allowed pharmacists to initiate drug 
therapy only for certain diseases and drug therapies only, while 34.60 percent of the 
respondent hospitals allowed pharmacists to initiate drug therapy for all patients, 
regardless of disease or treatment category.   
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Table 18. Proportion of Hospitals that Authorize Pharmacists to Change Duration of 
Drug Therapy 
________________________________________________________________________ 
 Percentage of  Hospitals with CDTM Authorizing Activity 
 ___________________________________________________ 
CDTM Activity For all patients For certain diseases For any patients 
  and therapies only 
________________________________________________________________________ 






Table 19. Proportion of Hospitals that Authorize Pharmacists to Adjust a Drug's strength 
________________________________________________________________________ 
 Percentage of  Hospitals with CDTM Authorizing Activity 
 ___________________________________________________ 
CDTM Activity For all patients For certain diseases For any patients 
  and therapies only 
________________________________________________________________________ 





Proportion of Hospitals that Authorize Pharmacists to  
Change a Drug's Dosage Form 
Table 20 shows the proportion of hospitals that allow pharmacists to "change a 
drug's dosage form" for patients as part of CDTM.  Of the 183 hospitals that had CDTM, 
80.67 percent of the respondents indicated that pharmacists in their facility were 
authorized to initiate drug therapy for any patients.  28.47 percent of respondent hospitals 
only allowed pharmacists to initiate drug therapy for certain diseases and drug therapies, 
while 42.43  percent of the respondent hospitals allowed pharmacists to initiate drug 
therapy for all patients, regardless of disease or treatment category.  This CDTM activity 
is unusual since it is one of only two activities for which a larger percentage of hospitals 
allowed pharmacists to change a drug's dosage form for all patients than allowed 
pharmacists to change drug dosage forms only for specific patients.   
Proportion of Hospitals that Authorize Pharmacists to Change a  
Drug's Frequency of Administration 
Table 21 shows the proportion of hospitals that allow pharmacists to "change a 
drug's frequency of administration" for patients as part of CDTM.  Of the 183 hospitals 
that had CDTM, 83.1 percent of the respondents indicated that pharmacists in their 
facility were authorized change a drug's frequency of administration for any patients.  
50.80 percent of respondent hospitals only allowed pharmacists to change a drug's 
frequency of administration for certain diseases and drug therapies, while 30.71 percent 
of the respondent hospitals allowed pharmacists to change a drug's frequency of 




Table 20. Proportion of Hospitals that Authorize Pharmacists to Change a  
Drug's Dosage form 
_______________________________________________________________________  
 Percentage of  Hospitals Authorizing Activity 
 __________________________________________________  
CDTM Activity For all patients For certain diseases For any patients 
  and therapies only 
_______________________________________________________________________  






Table 21. Proportion of Hospitals that Authorize Pharmacists to Change a Drug's 
Frequency of Administration 
________________________________________________________________________ 
 Percentage of  Hospitals Authorizing Activity 
 ___________________________________________________ 
CDTM Activity For all patients For certain diseases For any patients 
  and therapies only 
________________________________________________________________________ 
Change a Drug's 30.71 50.80 83.10  






Proportion of Hospitals that Authorize Pharmacists to Change a  
Drug's Route of Administration 
Table 22 shows the proportion of hospitals that allow pharmacists to "change a 
drug's route of administration" for patients as part of CDTM.  53.40 percent of the 183 
hospitals that had CDTM indicated that pharmacists in their facility were authorized to 
change a drug's route of administration for any patient.  26.79 percent of respondent 
hospitals only allowed pharmacists to change a drug's route of administration for certain 
diseases and drug therapies, while 28.47 percent of the respondent hospitals allowed 
pharmacists to change a drug's route of administration for all patients, regardless of 
disease or treatment category.  This is the second activity for which a larger percentage of 
hospitals allowed pharmacists to change a drug's dosage form for all patients than 
allowed pharmacists to change drug dosage forms only for specific patients, however the 
difference in percentages is low as compared to "changing drug dosage form".   
Proportion of Hospitals that Authorize Pharmacists to 
 Hold a Drug 
Table 23 shows the proportion of hospitals that allow pharmacists to "hold a 
drug" for patients as part of CDTM.  Of the 183 hospitals that responded yes to having 
any pharmacists involved in CDTM, 68.08 percent of the respondents indicated that 
pharmacists in their facility were authorized to hold a drug for any patient, 20.66 percent 
of respondent hospitals allowed pharmacists to hold a drug for certain diseases and 
therapies only, while 11.01 percent of the respondent hospitals allowed pharmacists to 
hold a drug for all patients, regardless of disease or treatment category. 
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Table 22. Proportion of Hospitals that Authorize Pharmacists to Change a Drug's  
Route of Administration 
 _______________________________________________________________________ 
 Percentage of  Hospitals Authorizing Activity 
 ___________________________________________________ 
CDTM Activity For all patients For certain diseases For any patients 
  and therapies only 
 _______________________________________________________________________ 







Table 23. Proportion of Hospitals that Authorize Pharmacists to Hold a Drug 
 _______________________________________________________________________ 
 Percentage of  Hospitals Authorizing Activity 
 __________________________________________________  
CDTM Activity For all patients For certain diseases For any patients 
  and therapies only 
 _______________________________________________________________________ 





Proportion of Hospitals that Authorize Pharmacists to  
Discontinue a Drug 
Table 24 shows the proportion of hospitals that allow pharmacists to "discontinue 
a drug" for patients as part of CDTM.  Of 183 hospitals with CDTM, 50.24 percent of the 
respondents indicated that pharmacists in their facility were authorized to discontinue a 
drug for any patient,  32.2 percent of respondent hospitals allowed pharmacists to 
discontinue a drug for certain diseases and therapies only, while 17.30 percent of the 
respondent hospitals allowed pharmacists to discontinue a drug for all patients, regardless 
of disease or treatment category.  The distribution was almost identical to that of 
hospitals that allowed pharmacists to "hold a drug". 
Proportion of Hospitals that Authorize Pharmacists to  
Order Laboratory or Related Tests 
Table 25 shows the proportion of hospitals that allow pharmacists to "order 
laboratory or related tests" for patients as part of CDTM.  90.77 percent of 183 
respondent hospitals with CDTM indicated that pharmacists in their facility were 
authorized to order laboratory or related tests for any patients, which makes "ordering 
laboratory or related tests"  the most common CDTM activity being performed by 
pharmacists at all respondent hospitals.  57.49 percent of respondent hospitals allowed 
pharmacists to initiate drug therapy only for certain diseases and drug therapies, while 
31.26  percent of the respondent hospitals allowed pharmacists to initiate drug therapy for 
all patients, regardless of disease or treatment category.   
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Table 24. Proportion of Hospitals that Authorize Pharmacists to Discontinue a drug 
________________________________________________________________________ 
 Percentage of  Hospitals Authorizing Activity 
 ___________________________________________________ 
CDTM Activity For all patients For certain diseases For any patients 
  and therapies only 
________________________________________________________________________ 





Table 25. Proportion of Hospitals that Authorize Pharmacists to Order Laboratory or 
Related Tests 
________________________________________________________________________ 
 Percentage of  Hospitals Authorizing Activity 
 ___________________________________________________ 
CDTM Activity For all patients For certain diseases For any patients 
  and therapies only 
________________________________________________________________________ 
Order Laboratory 31.26 57.49 90.77 





CDTM Activities by Disease or Treatment Areas  
Table 26 lists the diseases or treatment areas for which pharmacists were involved 
in CDTM.  Pharmacists were most frequently involved in CDTM for infectious diseases 
or antibiotics, anticoagulants, and parenteral nutrition.  The binomial proportions and 95 
percent confidence intervals for the three most common disease or treatment areas are as 
follows:  52.4 percent of all hospitals with a 95 percent confidence interval of (46.7-58.1) 
provided CDTM for Anticoagulation, 44.8 percent of all hospitals with a 95 percent 
confidence interval of (39.0-50.6) provided CDTM. for  Infectious Diseases  and 32.6 
percent  of all hospitals with a confidence interval of (27.2-38.0) provided CDTM for 
Parenteral Nutrition.  The disease/treatment categories included in the survey were 
Anticoagulation, Diabetes, Hypertension, Asthma, Emergency contraception, 
Dyslipidimias, Heart Failure, Infectious disease, General medicine, Smoking cessation, 
Pain management, Parenteral nutrition and Immunization.  For each of these categories, 
pharmacy directors were asked to indicate which specific CDTM activities were being 
carried out by pharmacists in their hospitals for patients of that particular category.  This 
information is summarized in Table 27.  For the treatment category "anticoagulation", 
across all hospitals hospitals that allowed CDTM, eighty-one percent allowed CDTM for 
anticoagulation patients.  The most common CDTM activities for patients getting 
anticoagulation therapy in hospitals with CDTM were ordering of laboratory tests 
(allowed by sixty-nine percent of all hospitals with CDTM), adjusting a drug's strength 
(allowed by sixty-one percent of all CDTM hospitals) and holding a drug (sixty percent 
of CDTM hospitals).  Two of these three activities are also the most common CDTM 
activities across all treatment/disease categories; however "holding a drug" is more 
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common in anticoagulation patients as compared to patients in general.  Therefore the 
trend within anticoagulation does not mirror the trend across all diseases.  In the case of  
infectious diseases, while the top three most common activities remains the same as for 
all diseases, the order is reversed.  The most commonly allowed CDTM activity for 
infectious disease patients was found to be adjusting a drug's strength, which was allowed 
by sixty-seven percent of all CDTM hospitals, followed by changing a drug's route of 
administration (sixty-two percent of CDTM hospitals) and then ordering of laboratory 
tests (fifty-six percent of CDTM hospitals).  Therefore it can be seen that the extent of 
CDTM activities by pharmacists varied by disease or treatment area.  While more 
hospitals allowed pharmacists to adjust a drug’s strength for patients taking 
anticoagulants or antibiotics, fewer hospitals allowed pharmacists to adjust a drug’s 
strength for patients with hypertension.  Pharmacists were seen to have almost zero 
involvement in any kind of CDTM activity for Emergency Contraception.  Asthma was 
the disease/treatment category with the second lowest percentage of pharmacist 
involvement, with pharmacists in only four percent of all hospitals that had some form of 
CDTM being involved in CDTM for Asthma patients.   
Reimbursement for CDTM activities 
Percentage of Hospitals Charging a Fee for CDTM Services 
Table 27 shows the sample distribution of responses of hospitals based on 
whether or not the hospital charged any sort of fee for the CDTM services being provided 
to patients.    Of the 183 hospitals that had responded "Yes" to having CDTM, only 
twenty-five pharmacy directors indicated that patients were charged a fee for CDTM 
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Table 26.  Proportion of CDTM Activities Allowed by Disease/Treatment Category in 
Hospitals with CDTM 
________________________________________________________________________  
  










________________________________________________________________________    
Anticoagulation 80.4 34.1 33.5 61.1 25.4 53.0 19.5 60.0 33.0 69.2 
Diabetes 20.13 8.1 5.4 10.8 7.6 11.4 5.9 12.4 10.3 11.4 
Hypertension 5.9 4.9 3.8 5.4 6.5 8.1 3.8 8.1 4.9 4.9 
Asthma 2.2 2.2 3.2 2.7 3.2 3.8 2.7 2.7 2.7 1.6 
Emergency 0.5 0.5 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 
Contraception 
Dyslipidemias  11.7 5.9 5.4 7.0 4.9 6.5 4.3 6.5 3.8 5.9 
Heart Failure 9.5 5.4 5.9 5.9 5.4 7.6 4.9 5.9 3.2 7.6 
Infectious Diseases 69.3 24.9 34.6 65.9 38.9 62.7 30.8 48.1 29.2 56. 2 
General Medicine 26.3 8.6 10.3 17.8 16.2 17.3 14.6 14.1 12.4 14.6 
Smoking Cessation 12.3 6.5 3.8 8.6 5.4 7.0 5.4 7.0 4.9 4.9 
Pain Management 21.1 9.7 9.2 14.6 9.2 11.4 8.1 10.8 8.6 9. 2 
Parenteral Nutrition 50.4 21.6 20.5 38.4 20.0 24.9 14.6 25.9 19.5 40. 5 

















































































































































services, which means that only 13.7 percent of the respondent hospitals received 
reimbursement for CDTM activities performed by a pharmacist.  These percentages are 
in terms of the number of hospitals that had some kind of CDTM service provided.  In 
terms of total number of respondents in the sample, 9.7 percent of the hospitals charged a 
fee for CDTM. 
Distribution of CDTM Activities for Which Hospitals Charge a Fee  
Table 28 shows the sample distribution of the CDTM activities for which 
hospitals charge a fee.  Out of 283 respondents, twenty-five pharmacy directors indicated 
"Yes" to the question "Does your hospital charge a fee for CDTM services?"  Of these 
twenty-five pharmacy directors that indicated that their hospitals charged a fee for CDTM 
services, twenty-three respondents volunteered further information on the type of patients 
that were charged a fee.  Nineteen (82.6 percent) of these hospitals only charged 
outpatients for CDTM services, while three (thirteen percent) charged only inpatients for 
CDTM.  Only one hospital charged both inpatients as well as outpatients for CDTM 
activities performed by a pharmacist.   
Associations between Hospital Characteristics and CDTM Use 
Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by Institution Ownership 
Associations between Institution Ownership and CDTM use were tested using 
logistic regression.  The results are summarized in Tables 29 and 31.  The p-value for the 
test was less than the a priori alpha 0.05, indicating that there was a significant 
association between Institution Ownership and CDTM use.  This implied that the 
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Table 27. Proportion of Hospitals Charging a Fee for CDTM services 
________________________________________________________________________ 
   Cumulative Cumulative 
Residency Frequency Percent Frequency  Percent  
   (N=183) 
________________________________________________________________________ 
No Fee charged  158 86.33 158 86.63      





Table 28. Distribution of Hospitals Charging a Fee for CDTM by whether Charged for 
Inpatients, Outpatients or Both 
_________________________________________________________________________  
   Cumulative Cumulative 
Residency Frequency Percent Frequency  Percent  
       (N=23) 
________________________________________________________________________ 
Inpatient Only 3 13.04 3 13.04   
Outpatient Only 19 82.60 22 95.64 





likelihood of the hospital having CDTM differed based on whether the institution was 
Private (Non Profit), Government or Private (for Profit).  Logistic regression was carried 
out using "Private (Non Profit)" as the reference category and it was found that 
Government hospitals were 0.25 times as likely as Private (non profit) hospitals to have 
CDTM, while Private (for profit) hospitals were 0.6 times as likely as Private (Non 
Profit) hospitals to have CDTM, though the difference was not significant in this case.  
Combining the two categories that were not found to be statistically different into a single 
"Private" category, logistic regression was carried out again using "Government 
hospitals" as the reference category.  It was found that Private hospitals were 3.3 times 
more likely to have CDTM than government hospitals (p<0.001). 
Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by Institution Classification 
Associations between Institution Classification and CDTM use were tested using 
chi square tests and logistic regression.  The results are summarized in Tables 29 and 31.  
The p-value for the test was greater than the a priori alpha 0.05, indicating that there were 
no significant associations between Institution Classification and CDTM use.   
Associations between Institution Classification and CDTM use were tested using 
chi square tests and logistic regression.  The results are summarized in Tables 29 and 31.  
The p-value for the test was greater than the a priori alpha 0.05, indicating that there were 
no significant associations between Institution Classification and CDTM use.   
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Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by City Population 
Associations between  population of the city the hospital is located in and CDTM 
use were tested using logistic regression.  The results are summarized in Tables 29.  The 
p-value for the test was less than the a priori alpha 0.05, indicating that there was a 
significant association between city population and CDTM use.  This implied that the 
likelihood of the hospital having CDTM differed based on the population bracket that the 
city that the hospital was located in fell under.   Logistic regression was carried out using 
cities with ">500,000 people" as the reference category.  It was found that hospitals 
located in cities with between 25,000 and 500,000 people were 1.3 times as likely to have 
CDTM as cities with populations greater than 500,000 (p<0.05).  On the other hand 
hospitals in cities with less than 5000 people were only 0.15 times as likely to have 
CDTM as hospitals in cities with more than 500,000 people (p<0.001).  The other 
categories were not found to differ significantly from the reference category.   
Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by Bed Size 
Associations between bed size and CDTM use were tested using logistic 
regression.  The results are summarized in Tables 29.  The p-value for the test was less 
than the a priori alpha 0.05, indicating that there was a significant association between 
bed size and CDTM use.  Logistic regression was carried out using "100 to 199 beds" as 
the reference category for hospital bed size and it was found that only hospitals with 
between 6 and 49 beds differed significantly with respect to reference group regarding 
likelihood of having CDTM.  Combining categories that were not found to be statistically 
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different into a single "bed size >50" category, logistic regression was carried out again 
using bed size "between 6-49 beds" as the reference category.  It was found that hospitals 
with more than fifty beds were 2.5 times more likely to have CDTM as compared to 
hospitals with six to forty-nine beds (p=0.005) 
Associations between Pharmacy Director Characteristics and CDTM Use 
Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by Respondent Age 
Associations between Pharmacy director age and CDTM use were tested using 
logistic regression.  The results are summarized in Table 29.  The p-value for the test was 
greater than the a priori alpha 0.05, indicating that there were no significant associations 
between Pharmacy director Age and CDTM use.   
Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by Respondent Gender 
Associations between Pharmacy director gender and CDTM use were tested using 
logistic regression.  The results are summarized in Table 29.  The p-value for the test was 
greater than the a priori alpha 0.05, indicating that there were no significant associations 
between Pharmacy director Gender and CDTM use.   
Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by Respondent Age 
Associations between Pharmacy director age and CDTM use were tested using 
logistic regression.  The results are summarized in Table 29.  The p-value for the test was 
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greater than the a priori alpha 0.05, indicating that there were no significant associations 
between Pharmacy director Age and CDTM use.   
Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by Pharm.D. degree received by Pharmacy director 
Logistic regression was used to determine whether the likelihood of a hospital 
having CDTM was affected by the pharmacy director having or not having a Pharm.D.  
degree.  The results are summarized in Table 29.  The p-value for the test was 0.02, less 
than the a priori alpha 0.05.  This indicates that there was a significant associations 
between Pharmacy director having a Pharm.D.  degree and CDTM use.  Logistic 
regression was carried out using hospitals whose pharmacy directors did not have a 
Pharm.D.  degree ("No degree") as the reference category.  It was found that hospitals 
with pharmacy directors that had a Pharm.  D.  degree were  1.8 times as likely to have 
CDTM as hospitals whose pharmacy directors had some other degree (p<0.05).   
Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by Pharmacy Director Licensure Time 
Associations between Pharmacy director licensure time and CDTM use were 
tested using logistic regression.  The results are summarized in Table 29.  The p-value for 
the test was greater than the a priori alpha 0.05, indicating that there were no significant 
associations between Pharmacy director licensure time and CDTM use.   
Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by Pharmacy Director Residency Completed 
Associations between Pharmacy director having completed a residency and 
CDTM use were tested using logistic regression.  The results are summarized in Table 
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29.  The p-value for the test was greater than the a priori alpha 0.05, indicating that there 
were no significant associations between Pharmacy director residency completed and 
CDTM use in the hospital.   
Comparison of Hospitals with and without Collaborative Drug Therapy Management 
(CDTM) by Pharmacy Director Special Certification  
Associations between Pharmacy director having received a special certification 
and CDTM use were tested using logistic regression.  The results are summarized in 
Table 30.  The p-value for the test was greater than the a priori alpha 0.05, indicating that 
there were no significant associations between Pharmacy director receiving a special 
certification and CDTM use in the hospital.   
Perceptions of CDTM  
Pharmacy Director perceptions of Collaborative Drug Therapy Management 
(CDTM) were assessed by asking respondents to rate their agreement with 27 items 
regarding views on CDTM on a 5 point Likert scale, where 1 = strongly disagree, 2 = 
disagree, 3 = neutral, 4 = agree, and 5 = strongly agree.  The "Perceptions Scale" 
consisted of 27 items assessing respondents’ opinions about the (1) range and scope of 
practice in CDTM (6 items), (2) support for CDTM by other health care providers and 
administrators in the hospital (9 items), (3) strategic value provided by collaborative 
practice to the pharmacy (3 items), (4) financial value created by collaborative practice (5 
items), and (5) nature of current state regulations that affect collaborative practice (4 




Table 29. Associations between Demographic Characteristics and CDTM 
 ________________________________________________________________________  
Variable Odds Ratio 95% C.I.  p value 
 _______________________________________________________________________   
Bed size   0.006 
 100 to 199 Reference Category   
 200 to 599 0.77 0.34 - 1.77 0.545 
 50 to 99 0.86 0.86 - 0.35 0.735 
 6 to 49 0.34 0.16 - 0.73 0.006 
Bed size (condensed)1   0.005 
 6 to 49 Reference Category   
 More than 50 2.51 1.51 - 4.23 0.005 
City Population   <0.001 
 More than 500,000 Reference Category   
 100,000 to 499,999 1.30 0.49 - 3.40 0.026 
 25,000 to 99,999 1.36 0.55 - 3.38 0.009 
 5,000 to 24,999 0.49 0.22 - 1.10 0.181 
 Less than 4,999 0.15 0.05 - 0.43 <0.001 
Institution Ownership   <0.001 
 Private(Non Profit) Reference Category   
 Government 0.25 0.13 - 0.47 <0.001 
 Private(for Profit) 0.57 0.30 - 1.05 0.654 
Institution Ownership2   <0.001 
 Government Reference Category   
 Private 3.3 1.83 - 5.89 <0.001 
Doctor of Pharmacy Degree   0.020 
 No degree Reference Category   
 Degree 1.83 1.09 - 3.05 0.021 
 ________________________________________________________________________ 
 
1,2Groups that did not differ significantly were combined 
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Table 30. Associations between Demographic Characteristics and CDTM 
 ________________________________________________________________________  
Variable Odds Ratio1 95% C.I.  p value 
 _______________________________________________________________________   
Institution Classification   0.215 
 Short Term General Reference Category   
 Long Term General 0.48 0.19 - 1.21 0.284 
 Psychiatric 0.48 0.17 - 1.33 0.478 
 Other 1.12 0.53 - 2.33 0.324 
Gender   0.3814 
 Female Reference Category   
 Male 1.26 0.76 - 2.10 0.363 
Age   0.246 
 35 to 45 years Reference Category   
 45 to 54 years 1.52 0.73 - 3.15 0.261 
 55 to 64 years 1.17 0.62 - 2.38 0.627 
 Less than 34 years 3.21 0.97 - 10.56 0.055 
 More than 65 years 0.67 0.19 - 2.33 <0.535 
Residency   <0.137 
 No residency Reference Category   
 Has residency 1.71 0.84 - 3.47 <0.137 
Certification   0.051 
No certification Reference Category   
Certification 1.88 0.99 - 3.53 0.051 
 ________________________________________________________________________ 
1Logistic regression run on each variable for the binary outcome variable "Engaged in 
CDTM" 
 




These items were further summated to form four scales, namely, the support for 
CDTM scale (eight items), the strategic impact of CDTM scale (three items), the 
financial impact of CDTM scale (four items), and the regulation affecting CDTM scale 
(four items).  These scales were based on a psychometric assessment of the survey in a 
previous study (Thomas et al.  2003) 
Frequency Distribution of Responses on Opinions About Current Practice  
There was a good spread in ratings on each of the items in the "Perceptions Scale" 
( appendix G).  When we look at the ratings spread for each individual item, several items 
have a distribution that is skewed towards the right (after reverse coding the negative 
statements), which implies that the general opinion leaned more towards agreement with 
positive views on CDTM.  This could interfere with analysis.  However the summated 
scales had a more uniform spread with no pronounced skewness. 
Mean Scale Scores for Support for CDTM, Strategic Impact of CDTM, Financial Impact 
of CDTM and Regulations for CDTM  
Means and standard deviations were calculated for each of the 27 survey items.  
For surveys missing observations for no more than 2 of the 27 items on perceptions 
regarding CDTM, the mean score on an item was entered for missing values.  For surveys 
missing observations for more than two items, none of the responses were used in the 
analysis of perceptions regarding CDTM.  Items regarding perceptions on CDTM that 
were negatively worded were reversed scored for analysis and scale scoring.  As 
discussed, the 27 items on the Perceptions Scale were further summated to form four 
scales, namely, the support for CDTM scale (eight items), the strategic impact of CDTM 
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scale (three items), the financial impact of CDTM scale (four items), and the regulation 
affecting CDTM scale (four items).  Ratings on each scale were added and divided by the 
number of items in the scale, to obtain a score ranging from one to five.  Scores close to 
one indicate strong disagreement and scores close to five indicate strong agreement with 
the opinion on CDTM.  Items in the CDTM scale were scored such that higher scores 
represent more positive impact of CDTM.   These scores are summarized in Table 31. 
Pharmacy Directors Opinions on the Support from Healthcare Providers 
The scale for the "Support for CDTM" had a mean of 3.98±0.54 and a median of 
4.0.  Scores greater than 3 indicate a positive attitude towards Support from healthcare 
providers. The closer the scores are to 5, the higher the support. Based on the mean scale 
scores, pharmacy directors perceived that CDTM was supported by health care providers 
and hospital administrators.   
Pharmacy Directors Opinions on the Strategic Impact of CDTM 
The scale for the "Strategic Impact of CDTM" had a mean of 3.87±0.66 and a 
median of 4.0.  Scores greater than 3 indicate a positive attitude towards Support from 
healthcare providers. The closer the scores are to 5, the higher the support.  Since the 
score is less than 3, it indicates a negative attitude towards the Effect of CDTM 
Regulations. However, since it is not much less than 3 (2.77), the opinions are not highly 
negative. Based on the mean scale scores, pharmacy directors perceived that CDTM had 
a positive strategic impact.   
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Pharmacy Directors Opinions on the Financial Impact of CDTM 
The scale for the "Financial Impact of CDTM" had a mean of 2.94±0.79 and a 
median of 3.0.  Scores greater than 3 indicate a positive attitude towards Support from 
healthcare providers. The closer the scores are to 5, the higher the support.  Based on the 
mean scale scores, pharmacy directors perceived that CDTM had little or no financial 
impact.   
Pharmacy Directors Opinions on the Effect of CDTM Regulations 
The scale for the " Effect of CDTM Regulations " had a mean of 2.77±0.69 and a 
median of 3.0.  Scores greater than 3 indicate a positive attitude towards Support from 
healthcare providers. The closer the scores are to 5, the higher the support.  Since the 
score is less than 3, it indicates a negative attitude towards the Effect of CDTM 
Regulations. However, since it is not much less than 3 (2.77), the opinions are not highly 
negative.  Based on the mean scale scores, pharmacy directors perceived that CDTM had 
suffered slightly due the state regulations.   
Associations between Perceptions of CDTM and CDTM use 
  ANOVA was used to determine if there was any difference in perceptions 
between hospitals with and without CDTM.   
Associations between Support for CDTM scale scores and CDTM  
The ANOVA test found significant associations between the Support for CDTM 
Scale and CDTM (p<0.0001).  Pharmacy Directors for hospitals with collaborative drug 




Table 31. Perceptions of Collaborative Drug Therapy Management. 
________________________________________________________________________   
  Standard 
Response Mean Deviation Minimum Maximum Median 
________________________________________________________________________   
Support for CDTM 3.9 0.4 1.3 4.5 3.3 
Strategic Impact of CDTM 3.8 0.5 2.1 5.0 4.0 
Financial Impact of CDTM 2.9 0.8 1.0 5.0 3.0 
Regulations for CDTM 2.7 0.7 1.0 5.0 3.0 
________________________________________________________________________  
1Mean based on an average score of scale items where 1 = strongly disagree, 2 = 
disagree, 3 = neutral, 4 = agree, and 5 = strongly agree. 
2p-values based on ANOVA comparison tests between hospitals that had CDTM and 







significantly higher than the mean score for Pharmacy Directors at hospitals without 
CDTM (3.58), meaning that they perceived greater support for CDTM as compared to 
pharmacy directors of hospitals without CDTM.  
Associations between Strategic Impact of CDTM scale scores and CDTM  
The ANOVA test found significant associations between the Strategic Impact of 
CDTM Scale and CDTM (p<0.0001).  Pharmacy Directors for hospitals with 
collaborative drug therapy management had higher mean scores for the Strategic impact 
scale at 4.06, meaning that they perceived greater strategic impact of CDTM as compared 
to pharmacy directors of hospitals without CDTM, who had a mean score of 3.05 for the 
same scale. 
Associations between Financial Impact of CDTM scale scores and CDTM  
The ANOVA test did not find any significant associations between the Financial 
Impact of CDTM Scale and CDTM (p=0.35).  Pharmacy directors' perceptions of the 
financial impact of CDTM was not dependent on whether or not their hospital had 
CDTM. 
Associations between Financial Impact of CDTM scale scores and CDTM  
The ANOVA test did not find any significant associations between the Financial 
Impact of CDTM Scale and CDTM (p=0.35).  Pharmacy directors' perceptions of the 




Associations between Effect of CDTM Regulations scale scores and CDTM  
The ANOVA test did not find any significant associations between the Effect of 
CDTM Regulations Scale and CDTM (p=0.35).  Pharmacy directors' perceptions of the  
impact of CDTM regulations was not dependent on whether or not their hospital had 
CDTM. 
Associations between Hospital Characteristics and Pharmacy director Perceptions of 
CDTM  
Analysis of variance was used to determine associations between Pharmacy 
Director Perceptions of CDTM and the demographic characteristics of the hospital.   
Associations between Hospital Characteristics and Support for CDTM scale scores 
Significant associations were found between the support for CDTM and 
institution ownership, bed size, and the population of the city in which the institution was 
located (p<0.05).  Items in the CDTM scale were scored such that higher scores represent 
more positive impact of CDTM.  Newman-Keuls multiple means comparison tests found 
a significant difference between Private (Non-Profit) and Government hospitals only.  
Pharmacy directors for private (Non-Profit) hospitals perceived greater support for 
CDTM from the hospital staff as compared to pharmacy directors in hospitals owned by 
the government (4.1 vs. 3.8 respectively).  Hospitals with six to forty-nine beds had 
significantly lower perceptions of support for CDTM at 3.8 compared to hospitals with 
more than fifty beds (4.04 to 4.1).  Similarly, pharmacy directors at hospitals in cities 
with less than 5,000 people had significantly lower scores for the Support for CDTM 




Table 32. Mean Scale Scores for Support for CDTM, Strategic Impact of CDTM, 
Financial Impact of CDTM and Regulations for CDTM 
________________________________________________________________________  
  Mean Scores for Hospitals 
   _____________________________  
  
Response With CDTM  Without CDTM p-value 
________________________________________________________________________   
Support for CDTM 4.19 3.58  <0.001 
Strategic Impact of CDTM 4.06 3.05  <0.001 
Financial Impact of CDTM 2.97 2.87  0.350 
Regulations for CDTM 2.79 2.75  0.680 
________________________________________________________________________ 
1Mean based on an average score of scale items where 1 = strongly disagree, 2 = 
disagree, 3 = neutral, 4 = agree, and 5 = strongly agree. 
2p-values based on ANOVA comparison tests between hospitals that had CDTM and 




Associations between Hospital Characteristics and Strategic Impact of CDTM scale 
scores 
 
Significant associations were found between the strategic impact of CDTM and 
institution ownership, bed size, and the population of the city in which the institution was 
located (p<0.05).  Items in the CDTM scale were scored such that higher scores represent 
more positive impact of CDTM.  Newman-Keuls multiple means comparison tests found 
a significant difference between Private and Government hospitals only.  Hospitals with 
six to forty-nine beds had significantly lower perceptions of impact of  CDTM at 3.6 
compared to hospitals with more than fifty beds (3.9 to 4.0).  Similarly, pharmacy 
directors at hospitals in cities with less than 5,000 people had significantly lower scores 
for the Impact of CDTM scale at 3.4 when compared to hospitals in cities with more than 
100,000 people (3.8). 
Associations between Hospital Characteristics and  Financial Impact of CDTM scale 
scores  
 
No significant associations were found between the financial impact of CDTM 
and any hospital characteristic including institution ownership, institution classification, 
bed size, and the population of the city in which the institution was located (p>0.05).   
Associations between Hospital Characteristics and CDTM Regulations scale scores  
No significant associations were found between the CDTM Regulations scale 
scores and any hospital characteristic including institution ownership, institution 
classification, bed size, and the population of the city in which the institution was located 
(p>0.05).   
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Associations between Pharmacy director Perceptions of CDTM and  
Pharmacy Director Characteristics 
Analysis of variance was used to determine associations between Pharmacy 
Director Perceptions of CDTM and the demographic characteristics of the respondents.   
Associations between Pharmacy Director Characteristics and Support for CDTM scale 
scores  
 
Significant associations were found between the support for CDTM scale scores 
and Pharmacy Director certification and degree (p<0.05).  Pharmacy directors who had 
completed some certification related to the field perceived greater support for CDTM at 
their facilities compared to pharmacy directors that did not have any certification (4.1 vs. 
3.9 respectively).  Pharmacy directors that had a Pharm.D.  or a Doctor of Pharmacy 
degree had significantly higher scores for the Support for CDTM scale as compared to 
pharmacy directors with any other degree (4.0 vs. 3.9 respectively). 
Associations between Pharmacy Director Characteristics and Strategic Impact of CDTM 
scale scores  
Significant associations were found between the support for CDTM scale scores 
and Pharmacy Director certification (p=0.02).  Newman-Keuls multiple means 
comparison tests found that pharmacy directors who had completed some certification 
related to the field perceived greater strategic impact of CDTM at their facilities 
compared to pharmacy directors that did not have any certification (4.0 vs. 3.8 





Table 33. Associations between Support for CDTM and Hospital Characteristics 
 ________________________________________________________________________ 
       
Hospital Characteristic Number2 Mean NK Grouping F-value p-value1 
 ________________________________________________________________________ 
Institution  
Ownership (N=269)     5.19 0.006 
 Private nonprofit 139 4.08  A  
 Private for profit 70 3.91 B A  
 Government  60 3.83 B  
Institution  
Classification (N=269)     1.68 0.171 
 Short-term general 194 4.00  A 
 Long-term general  19 3.80  A 
 Psychiatric  16 3.76  A 
City Population (N=265)     4.54 0.002 
 Less than 4,999 28 3.71 B 
 5,000 to 24,999 81 3.86 B A 
 25,000 to 99,999 66 4.10  A  
 100,000 to 499,999 49 4.04  A  
 More than 500,000 41 4.12  A  
Bed Size (N=266)     5.18 0.002 
 6 to 49 96 3.81 B 
 50 to 99 53 4.06  A 
 100 to 199 48 4.04  A 
 200 to 599 69 4.11  A 
________________________________________________________________________ 
1p-value<0.05 is considered significant 




Table 34. Associations between Strategic Impact of CDTM and Hospital Characteristics 
 ________________________________________________________________________ 
       
Hospital Characteristic Number2 Mean NK Grouping F-value p-value1 
 ________________________________________________________________________ 
Institution  
Ownership (N=264)     50.07 <0.001 
 Private nonprofit 138 3.94  A  
 Private for profit 68 3.90  A  
 Government  58 3.68 B  
Institution  
Classification (N=264)     1.10 0.171 
 Short-term general 190 3.91  A 
 Long-term general  19 3.67  A 
 Psychiatric  16 3.70  A 
City Population (N=260)     4.28 0.002 
 Less than 4,999 27 3.44 B 
 5,000 to 24,999 79 3.81  A 
 25,000 to 99,999 66 3.96  A  
 100,000 to 499,999 49 3.97  A  
 More than 500,000 39 4.01  A  
Bed Size (N=269)     6.03 0.001 
 6 to 49 93 3.65 B 
 50 to 99 51 3.91  A 
 100 to 199 48 4.01  A 
 200 to 599 69 4.03  A 
________________________________________________________________________ 
1p-value<0.05 is considered significant 





Table 35. Associations between Financial Impact of CDTM and Hospital Characteristics 
 ________________________________________________________________________ 
       
Hospital Characteristic Number2 Mean NK Grouping F-value p-value1 
 ________________________________________________________________________ 
Institution  
Ownership (N=260)  0.20 0.812 
 Private nonprofit 136 2.93  A  
 Private for profit 66 2.93  A  
 Government  57 2.93  A  
Institution 
Classification (N=259)  1.10 0.170 
 Short-term general 188 2.97  A 
 Long-term general  19 2.84  A 
 Psychiatric  16 2.96  A 
City Population (N=256)  0.93 0.453 
 Less than 4,999 27 2.81  A 
 5,000 to 24,999 79 2.77  A 
 25,000 to 99,999 66 2.85  A  
 100,000 to 499,999 49 2.80  A  
 More than 500,000 39 2.58  A  
Bed Size (N=257)  0.90 0.437 
 6 to 49 93 3.06  A 
 50 to 99 51 2.94  A 
 100 to 199 48 2.86  A 
 200 to 599 69 3.06  A 
________________________________________________________________________ 
1p-value<0.05 is considered significant 




Table 36. Associations between Regulations for CDTM and Hospital Characteristics 
 ________________________________________________________________________ 
       
Hospital Characteristic Number2 Mean NK Grouping F-value p-value1 
 ________________________________________________________________________ 
Institution  
Ownership (N=264)     1.44 0.239 
 Private nonprofit 136 2.93  A  
 Private for profit 66 2.93  A  
 Government  57 2.93  A  
Institution  
Classification (N=264)     1.75 0.156 
 Short-term general 188 2.97  A 
 Long-term general  19 2.84  A 
 Psychiatric  16 2.96  A 
City Population (N=260)     1.00 0.410 
 Less than 4,999 27 2.81  A 
 5,000 to 24,999 79 2.77  A 
 25,000 to 99,999 66 2.85  A  
 100,000 to 499,999 49 2.80  A  
 More than 500,000 39 2.58  A  
Bed Size (N=262)     1.42 0.237 
 6 to 49 93 3.06  A 
 50 to 99 51 2.94  A 
 100 to 199 48 2.86  A 
 200 to 599 69 3.06  A 
________________________________________________________________________ 
1p-value<0.05 is considered significant 




Associations between Pharmacy Director Characteristics and Financial Impact of CDTM 
scale scores 
  
No significant associations were seen between the financial impact for CDTM 
scale scores and Pharmacy Director certification characteristics.  This implies that there 
was no difference in mean scores for the Financial Impact scale between pharmacy 
directors with different pharmacy director characteristics.  This implies that there was no 
difference between the two groups in terms of their perceptions of what the financial 
impact of CDTM has been. 
Associations between Pharmacy Director Characteristics and CDTM Regulations scale 
scores  
 
No significant associations were seen between the CDTM Regulations scale 
scores and any pharmacy director characteristic including age, gender, licensure time, 
degree or certification obtained or residency completed  (p>0.05).  This implies that there 
was no difference between the two groups in terms of their perceptions of how CDTM 
Regulations have affected practice.  
Future plans for CDTM activities. 
 Tables 41 and 42 provide data on the short-term (within one year) and the long-
term (beyond one year) plans of hospitals for changes in various aspects of CDTM.  In 
terms of the distribution of responses, the distribution was heavily skewed towards the 
right, with almost no respondents choosing the "Large decrease" or "Slight Decrease" 
option on the rating scale.  However looking at the responses can give us a good idea of 





Table 37. Associations between Support for CDTM and Pharmacy Director 
Characteristics 
 ________________________________________________________________________ 
       
Pharmacy Director  
Characteristic Number2 Mean NK Grouping F-value p-value1 
 ________________________________________________________________________ 
Gender (N=264)    0.67 0.512 
 Female 106 3.97  A 
 Male 157 3.99  A 
Age (N=260)    0.92 0.450 
 Less than 34 years 23 4.03 A 
 35 to 44 years 60 4.00  A 
 45 to 54 years 63 4.01  A 
 55 to 64 years 102 3.98  A 
 More than 65 years 12 3.69  A 
Residency (N=269)      0.97 0.326 
 Yes 45 4.06 A 
 No 224 3.97  A 
Pharm.D. (N=261)     4.87 0.020 
 Degree 136 4.05  A 
 No degree 135 3.90  B 
Certification (N=252)    5.21 0.023 
 Yes 62 4.12  A 
 No 197 3.93 B 
_______________________________________________________________________  
1p-value<0.05 is considered significant 




Table 38. Associations between Strategic Impact of CDTM and Pharmacy Director 
Characteristics 
 ________________________________________________________________________ 
       
Pharmacy Director  
Characteristic Number2 Mean NK Grouping F-value p-value1 
 ________________________________________________________________________ 
Gender (N=264)    0.62 0.538 
 Female 103 3.84  A 
 Male 153 3.90  A 
Age (N=260)    0.96 0.430 
 Less than 34 years 22 3.83  A 
 35 to 44 years 58 3.91  A 
 45 to 54 years 63 3.80  A 
 55 to 64 years 99 3.94  A 
 More than 65 years 11 3.60  A 
Residency (N=269)      0.50 0.480 
 Yes 44 3.94  A 
 No 218 3.86  A 
Pharm.D. (N=261)    0.15 0.700 
 Degree 136 4.05  A 
 No degree 135 3.99  A 
Certification (N=252)    5.21 0.0230 
 Yes 59 4.05  A 
 No 193 3.83 B  
________________________________________________________________________ 
1p-value<0.05 is considered significant 




Table 39. Associations between Financial Impact of CDTM and Pharmacy Director 
Characteristics 
 ________________________________________________________________________       
Pharmacy Director  
Characteristic Number2 Mean NK Grouping F-value p-value1 
 ________________________________________________________________________ 
Gender (N=264)    0.52 0.592 
 Female 99 2.88  A 
 Male 152 2.98  A 
Age (N=260)    0.34 0.852 
 Less than 34 years 22 2.82  A 
 35 to 44 years 54 2.89  A 
 45 to 54 years 63 2.94  A 
 55 to 64 years 98 2.99  A 
 More than 65 years 11 2.82  A 
Residency (N=269)        0.00 0.952 
 Yes 44 2.94  A 
 No 218 2.86  A 
Pharm.D. (N=261)     2.33 0.128 
 Degree 136 2.85 A 
 No degree 135 2.99  A 
Certification (N=247)    0.00 0.994 
 Yes 59 2.85  A 
 No 193 2.83  A 
________________________________________________________________________ 
1p-value<0.05 is considered significant 




Table 40. Associations between Regulations for CDTM and Pharmacy Director 
Characteristics 
 ________________________________________________________________________ 
       
Pharmacy Director  
Characteristic Number2 Mean NK Grouping F-value p-value1 
 ________________________________________________________________________ 
Gender (N=257)    0.91 0.402 
 Female 106 3.97  A 
 Male 157 3.99  A 
Age (N=260)    1.79 0.131 
Less than 34 years 22 3.83  A 
 35 to 44 years 58 3.91  A 
 45 to 54 years 63 3.80  A 
 55 to 64 years 99 3.94  A 
 More than 65 years 11 3.60  A 
Residency (N=269)      0.08 0.784 
 Yes 44 3.94  A 
 No 218 3.86  A 
Pharm.D. (N=261)    0.00 0.948 
 Degree 136 4.05  A 
 No degree 135 3.99  A 
Certification (N=247)    0.01 0.9286 
 Yes 59 4.05  A 
 No 193 3.83  A 
________________________________________________________________________ 
1p-value<0.05 is considered significant 




Since the data is heavily skewed towards "increase", we can conclude that in the 
short-term, hospitals with CDTM planned to increase the numbers of staff pharmacists 
involved in CDTM, CDTM protocols, and diseases or areas for which pharmacists 
provide CDTM.  These hospitals also had long-term plans to increase the number of 
CDTM protocols and diseases or areas for which pharmacists provide CDTM.  Looking 
at the mean and median scores obtained, it can be seen that the hospitals indicated larger 
planned increases in the long term than in the short term.  4.8 percent of hospitals had 
plans for a large increase in the number of CP protocols in the short term as opposed to 
18.42 percent of hospitals that had plans for a large increase in the long term. Similarly, 
6.02 percent of hospitals had plans for a large increase in the number of diseases or 
treatments their hospital authorized CDTM for  in the short term as opposed to 
18.42percent of hospitals that had plans for a large increase in the number of disease or 
treatment areas for CDTM  in the long term.  So more hospitals had plans for a long term 
increase than for a short term increase in CDTM.  This is also reflected in the mean 
scores for short term and long term plans.  
Perceived Barriers and Facilitators for CDTM. 
Table 43 lists perceived barriers for CDTM and Table 44 lists perceived 
facilitators for CDTM  as mentioned by respondents.  Lack of support from physicians 
and other medical staff (33.8 percent), shortage of pharmacists (26.3 percent), financial or 
reimbursement issues (12.6 percent), and pharmacist time constraints (12.1 percent)  were 
cited as the most frequent barriers to adopting CDTM.  Physician and other medical staff 




Table 41. Plans regarding Collaborative Drug Therapy Management. 
________________________________________________________________________ 
 Percent of Respondents Choosing Each Response 
 _______________________________________ 
 Large Slight No Slight Large 
Response Decrease Decrease Change Increase Increase 
________________________________________________________________________ 
Short Term Plans1 
Number of staff pharmacists involved 0.75 3.00 65.54 26.22 4.49 
Number of CP protocols 0.00 1.12 46.82 47.19 4.87 
Number of diseases/ therapies in which 0.00 0.75 45.49 47.74 6.02 
pharmacist provide CP 
Long Term Plans2 
Number of staff pharmacists involved 0.38 1.13 50.94 36.23 11.32 
Number of CP protocols 0.38 0.00 33.83 47.37 18.42 
Number of diseases/ therapies in which 0.38 0.00 27.55 53.58 18.49  
pharmacist provide CP 
________________________________________________________________________ 
1Short Term Plans are plans for the next one year 





Table 42. Means, Standard Deviation, Minimum, Maximum and Medians of Plans 
Regarding Collaborative Drug Therapy Management. 
________________________________________________________________________ 
 Percent of Respondents Choosing Each Response  
 _______________________________________ 
  Standard  
Response Mean Deviation Minimum Maximum Median 
________________________________________________________________________ 
Short Term Plans 
Number of staff pharmacists involved 3.3 0.6 1.0 5.0 3.0 
Number of CP protocols 3.5 0.6 2.0 5.0 4.0 
Number of diseases/ therapies in which 3.5 0.6 2.0 5.0 4.0 
 pharmacist provide CP 
Long Term Plans 
Number of staff pharmacists involved 3.5 0.7 1.0 5.0 3.0 
Number of CP protocols 3.8 0.7 1.0 5.0 4.0 
Number of diseases/ therapies in which 3.9 0.7 1.0 5.0 4.0 
 pharmacist provide CP 
________________________________________________________________________  
1Short Term Plans are plans for the next one year 






outcomes/reduction in medication errors (10.2 percent) were the most frequently 
mentioned facilitators of CDTM.  It is worth noting that physician support was both the 
most commonly cited facilitator as well as the most commonly cited barrier to CDTM 
(lack of physician support). 
Comparison of Current Extent of CDTM with that in 2003 
Since this study is the first to utilize the survey developed and validated by 
Thomas and colleagues for their survey of collaborative drug therapy management in 
hospitals (Thomas et al. 2003), comparing the results obtained in both surveys can give 
an estimate of the change in the extent of CDTM in U.S. hospitals over the last decade.  
The proportion of CDTM in hospitals reported in the 2003 study was compared with the 
proportion of CDTM in hospitals in this study using Chi-Square tests.  The 2003 study 
had reported that 50  percent of all respondent hospitals had CDTM.. In this study, 66 
percent of all respondent hospitals had CDTM.  This is a statistically significant increase 
from the proportion in 2003 (p<0.001).  Hence we can conclude that there has been an 
increase in the extent to which CDTM is used in U.S. hospitals over the last 10 years 
Tests for Response Bias 
To test for potential non-response bias, the first third of respondents were 
compared with the last third of respondents.  Based on ‘the continuum of resistance 
model’ late respondents can be used as a proxy for non-respondents in estimating non-
response bias, while early respondents are indicative of all respondents, hence the 
difference between the two will reflect the non-response bias (Voogt et al.  1998). 
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Table 43. Perceived Barriers to CDTM 
________________________________________________________________________ 
Perceived Barriers Number of  Percentage
 Respondents of Respondents 
 (N=198) 
________________________________________________________________________ 
Shortage of pharmacists 52 26.26 
Lack of support from physicians/medical staff 67 33.84 
Financial or reimbursement issues 25  12.63 
Pharmacist time constraint 24 12.12 
Pharmacist competencies 18 9.09 
Lack of upper administration support 10  5.05 
State legislation constraint 18 9.09 
Pharmacists’ unwillingness 15 7.58 
Lack of interest/understanding 7 3.54 
Lack of resources 28 14.14 
Technology constraints 2 1.01 
Lack of appropriate protocols 2 1.01 





Table 44. Perceived Facilitators to CDTM 
________________________________________________________________________ 
Perceived Facilitators Number of  Percentage
 Respondents of Respondents 
 (N=218) 
________________________________________________________________________ 
Physicians’ and other medical staff’s support 92 42.20 
Pharmacist competence 13 5.96 
Good relationship with healthcare providers 11 5.05 
Upper administration support 31 14.22 
Pharmacists’ desire 17 7.80 
Improved patient outcomes/reduction in errors 23  10.55 
Physician lack of time 10 4.59 
Legislation 7 3.21 
Financial gains 9 4.13 
Patient satisfaction 3 1.38 
Clinical rounds 3 1.38 
Formulary 3 1.38 





  Chi-square tests were used to compare categorical variables for early 
respondents and late respondents and Analysis of Variance tests were used to compare 
continuous variables for early and late respondents.  The characteristics of early and late 
respondents that were compared were the proportion of hospitals that engaged in CDTM, 
perceptions regarding CDTM, hospital characteristics, and pharmacy directors' 
characteristic.  There were no significant differences found between early and late 
respondents for any of the demographic characteristics.  However the early respondents 
had a significantly higher mean score for "Support for CDTM" as compared to the later 
respondents.   
In addition to comparing early and late respondents, the sample distribution on the 
basis of the number of beds in the hospitals (Bed Size) was compared to the distribution 
of bed sizes of the population.  The purpose of doing this was to determine whether the 
random sample that had been drawn differed significantly from the rest of the population 
in terms of demographic characteristics.  Bed Size was used as the parameter since bed 
size data was available for respondents as well as non respondents.  No significant 
differences were found between the bed size distribution of our sample and the rest of the 
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SUMMARY AND DISCUSSION 
The overall objective of the project was to study the extent and scope of 
collaborative drug therapy management (CDTM) in U.S. hospitals as well as pharmacy 
directors’ perceptions regarding CDTM.  There were four specific objectives of this 
study: 1) to assess the current extent, scope and perceptions of CDTM in U.S.  hospitals, 
2) to determine the associations between hospital characteristics, pharmacy director 
characteristics, and perceptions of CDTM, 3) to investigate hospitals' short-term and 
long-term plans regarding CDTM and 4) to identify pharmacy directors' views about the 
major facilitators and barriers for CDTM in hospitals. 
A mail survey developed and validated by Thomas et al.  (Thomas et al.  2006) 
was used to collect data.  The mail survey asked respondents to indicate whether any 
pharmacists in their hospital were engaged in CDTM or collaborative practice that 
involved the initiation or modification of drug therapy and  contained specific questions 
the extent and scope of CDTM activities in their institution.  The survey also had two 
additional open-ended questions that ask the respondents what they perceive to be the 
greatest barrier to CDTM as well as the greatest facilitator of CDTM. 
 Pharmacy directors' opinions on CDTM were assessed using twenty-seven items 
in the survey developed and validated by Thomas et al.  The items assessed respondents’ 
opinions about the range and scope of practice in CDTM (six items), the support for 
CDTM by other health care providers and administrators in the hospital (nine items), the 
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strategic value provided by collaborative practice to the pharmacy (three items), any 
financial value created by collaborative practice (five items), and nature of current state 
regulations that affect collaborative practice (four items).  Pharmacy director perceptions 
of CDTM were assessed using four scales of the CDTM scale: the support for CDTM 
scale (eight items), the strategic impact of CDTM scale (three items), the financial impact 
of CDTM scale (four items), and the regulations affecting CDTM scale (four items).  The 
support for CDTM scale assesses pharmacy director perceptions about the support for 
CDTM activities from the hospital staff, including medical staff and upper administration 
(Thomas et al. 2003).  Plans regarding CDTM were assessed using six items in the survey 
that collected information on whether the respondents had any plans to make changes in 
the categories: (1) number of staff pharmacists involved in CP,  (2) number of CP 
protocols and (3) number of diseases/ therapies in which pharmacist provide CP.  Each 
item was rated on a 5 point Likert scale previously described, that ranged from large 
decrease to large increase.  Means and standard deviations were calculated for each of the 
items and the percentage of respondents indicating each response was also calculated. 
Associations between hospital and pharmacy directors characteristics and CDTM use 
were tested using chi square tests and logistic regression.  Analysis of variance was used 
to determine associations between Pharmacy Director Perceptions of CDTM and the 
demographic characteristics of the hospital.  Newman-Keuls multiple means comparison 
tests were used for Post-hoc analysis in case of significant ANOVA tests.  To test for 
potential non-response bias, the first third of respondents were compared with the last 
third of respondents on the basis of the proportion of hospitals that engaged in CDTM, 
perceptions regarding CDTM, hospital characteristics, and pharmacy directors' 
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characteristics, and the sample distribution on the basis of the number of beds in the 
hospitals (Bed Size) was compared to the distribution of bed sizes of the population.   
Sample 
Surveys were completed by 283 out of 945 individuals who received surveys and  
satisfied inclusion and exclusion criteria, a response rate of 30.1 percent.  A majority of 
the hospitals in the study sample were privately owned  (89%) and classified as Short 
Term-General (73%).  The maximum concentration of hospitals was in cities with 5,000 
to 250,000 people (183 hospitals, 68.3 percent).   Most pharmacy directors were over 45 
years of age ( 63%) and approximately 60 percent of the participants were females.  72.5 
percent of all respondents, had received their license to practice Pharmacy more than 
fifteen years prior to the study.   Most pharmacy directors had not completed a residency 
(85%).  Approximately half of the respondents had a Doctor of Pharmacy degree, while 
56.7 percent of respondents had a Bachelor of Science in Pharmacy degree. 
Extent and Scope of CDTM 
Approximately sixty-five percent of U.S. hospitals authorized some of their 
pharmacists to engage in CDTM and sixty-six percent of all pharmacists employed at the 
hospitals were involved in providing CDTM services to patients.  A majority of the 
hospitals (60%) had written protocols in place for CDTM, which were mostly disease or 
treatment specific (37%), or general for several diseases or treatments (30%).   
 A similar study conducted by Thomas and colleagues in 2003 had found that 
approximately half of all U.S. hospitals had some pharmacists engaged in CDTM 
(Thomas et al. 2003).  Findings from this study indicate that the proportion of hospitals 
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that allow pharmacists to participate in CDTM over the last ten years has gone up by 
sixteen percentage points.  Such a result is in keeping with expectations of CDTM use 
increasing over the last decade with the increase in the number of states that have state 
laws and regulations enabling pharmacists to engage in CDTM from 16 states in 1996 
(Shefcheck and Thomas,1996) to  48 states with CDTM laws in 2014 (Weaver 2014).  
However the 2003 study found that almost eighty percent of all hospitals had written 
protocols in place for collaborative practice (Thomas et al. 2003), while this study had 
only sixty percent of all respondents indicating that their hospital had written protocols.  
So it would appear that the number of hospitals allowing CDTM has grown at a higher 
rate than the rate at which hospitals are introducing written protocols to regulate CDTM.   
CDTM Activities 
Most hospitals with CDTM allowed pharmacists to order laboratory tests [58.7% 
of all hospitals, 95% confidence interval for the percentage being (53 - 64.4)], adjust drug 
strength [57.9% of all hospitals, 95% confidence interval for the percentage being  (52.0 - 
63.8)] and change frequency of administration of drugs [53.8% of all hospitals, 95% 
confidence interval for the percentage being (48.0 - 59.6)].  However only 34 percent of 
hospitals allowed pharmacists to discontinue a drug, and approximately the same 
percentage of the hospitals (30.4%) allowed their pharmacists to initiate drug therapy.   
Findings from this study are consistent with past literature.  In a 1996 study by 
Fuller and colleagues, it was found that most CDTM protocols involved continuation of 
drug therapy or authorizing renewals, while initiation of therapy was the least commonly 
seen (Fuller et al. 2003).  In 2003, Thomas and colleagues surveyed U.S. hospitals and 
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reported that  most of the hospitals with CDTM authorized pharmacists to adjust a drug’s 
strength, order laboratory or related tests, and change a drug’s frequency of 
administration.  However, only 31.6 percent of the CDTM hospitals allowed pharmacists 
to discontinue a drug, and less than half of the CDTM hospitals (42.4%) allowed their 
pharmacists to initiate drug therapy.  These trends are similar to the trends seen in this 
study with adjusting a drug’s strength, ordering laboratory or related tests, and changing a 
drug’s frequency of administration still being the most common activities and initiating 
drug therapy being one of the least common activities.  However the percentage of 
hospitals allowing pharmacists to initiate drug therapy has reduced even more since 2003. 
 It was also seen that hospitals mostly permitted CDTM for the treatment/disease 
categories of Anticoagulation [52.4%, (95 % confidence interval = 46.7% - 58.1%)], 
Infectious Diseases [44.8%, (95 % confidence interval =39.0% - 50.6%)] and Parenteral 
Nutrition [32.6% (95 % confidence interval =27.2% - 38.0%)].  These findings are 
mostly consistent with those reported by Thomas and colleagues in 2003, who found that 
hospital pharmacists were most frequently involved in CDTM for infectious diseases or 
antibiotic therapy, anticoagulation, and parenteral nutrition, in that order.  While the three 
most common treatment areas has remained consistent over the last decade, this study 
found that anticoagulation therapy was now the most commonly provided therapy by 
CDTM pharmacists as opposed to infectious disease therapy in 2003.  
Reimbursement for CDTM activities 
Of the 276 responses received, only twenty-five pharmacy directors indicated that 
patients were charged a fee for CDTM services, which means that only nine percent of 
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the respondent hospitals were charging any kind of fee to patients for CDTM activities 
performed by a pharmacist.  Nineteen (82.6 percent) of these hospitals only charged 
outpatients for CDTM services. 
 In 2003, Thomas and colleagues reported that just over twelve percent of the 
hospitals with CDTM surveyed charged patients a fee for CDTM activities performed by 
a pharmacist. Findings from this study indicate that re-imbursement for CDTM activities 
is still very low, with only nine percent of respondent hospitals reporting charging 
patients a fee for CDTM activities. 
Associations between Hospital and Pharmacy Director Characteristics and CDTM Use 
Private hospitals were 3.3 times more likely to have CDTM than government 
hospitals.  Likelihood of having CDTM was also positively associated with the 
population of the city in which the hospital was located as well as the number of beds in 
the hospital, with hospitals in larger cities and with a greater number of beds having a 
significantly higher chance of having CDTM as compared to smaller cities and hospitals. 
A possible reason for this trend could be that larger or city-based hospitals have a larger 
number of patients admitted and the use of pharmacists to provide care under CDTM in 
these hospitals may help to increase efficiency by taking on some of the physicians 
'workload.   Likelihood of a hospital having CDTM was only significantly associated 
with one Pharmacy Director characteristic. It was found that hospitals with pharmacy 
directors that had a Pharm.D.  degree were  twice as likely to have CDTM as hospitals 
whose pharmacy directors had some other degree. 
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These findings are mostly consistent with prior literature where hospitals located 
in bigger cities and hospitals with greater bed sizes beds were reported as being more 
likely to have CDTM (Thomas e al. 2003).  However pharmacy director age has been 
reported as a significant predictor of the hospital having CDTM in past literature(Thomas 
et al. 2003) which is inconsistent with this study that did not find any significant 
associations between pharmacy director age and the likelihood of the hospital having 
CDTM. 
 Pharmacy director perceptions of  CDTM  
Pharmacy directors perceived positive support for CDTM in hospitals from health 
care providers and hospital administrators.  The Chi Square test found significant 
associations between the Support for CDTM Scale scores and CDTM (p<0.0001) and 
Pharmacy Directors for hospitals with collaborative drug therapy management had higher 
mean scores for the Support scale, meaning that they perceived greater support for 
CDTM as compared to pharmacy directors of hospitals without CDTM.  This is 
consistent with what was reported by Thomas and colleagues in 2003 who reported a 
significant association between the support for CDTM in hospitals and their likelihood of 
having CDTM.  A non-significant Chi-Square test result for associations between the 
Financial Impact of CDTM scale indicated that respondents perceived little or no 
financial impact of CDTM,  with just over nine percent of the hospitals that reported 
having some pharmacists engaged in CDTM charging patients a fee for pharmacists’ 
CDTM activities.  Similar results have been obtained in studies in other settings.  For 
example, in a study of community pharmacies in North Carolina, less than 21 percent of 
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pharmacies billed or received reimbursement for pharmaceutical care services provided 
by pharmacists (Zillich et al. 2002).   
However, CDTM was perceived to have a positive strategic impact with the 
median score for the Strategic Impact of CDTM scale given by pharmacy directors being 
4.0 (Scores closer to 5.0 indicated a more positive response).  A majority of the 
respondents agreed that CDTM activities enhance upper administration’s perceptions of 
the value of pharmacists (85%) and facilitate implementation of other pharmacy services 
(65%).  This is consistent with the results of a study by Kwint and colleagues in 2013 
who found significant associations between the extent of collaboration between 
physicians and pharmacists and implementation rate of recommendations arising from 
medication review (Kwint et al. 2013).  CDTM was also perceived to have a positive 
strategic impact in the 2003 study by Thomas and colleagues indicating that there has 
been no change in pharmacy director perceptions of the strategic impact of CDTM over 
the last decade.  
Associations between Perceptions of CDTM and CDTM Use 
Significant associations exist between pharmacy directors perceptions of the 
support for CDTM in their hospitals as well as the strategic impact of CDTM with 
CDTM use.  Pharmacy Director scores for perceived support for CDTM in hospitals that 
had form of  CDTM were significantly higher than the Pharmacy Director scores for 
perceived support for CDTM in hospitals that did not have any pharmacists involved in 
CDTM.  Respondents from hospitals with CDTM also perceived greater strategic impact 
of CDTM than those from hospitals without CDTM. These findings are consistent with 
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the results of the 2003 survey of pharmacy directors by Thomas and colleagues (Thomas 
et al. 2003).  Since support for CDTM was also identified as a major facilitator for 
CDTM, it can be expected that pharmacy directors of  hospitals where CDTM is being 
practiced would perceive greater support for CDTM as compared to hospitals without 
CDTM. 
Associations between Demographic Characteristics 
 and Pharmacy director Perceptions of CDTM  
Significant associations exist between the support for CDTM and institution 
ownership, bed size, and the population of the city in which the institution was located.  
Pharmacy directors for private (Non-Profit) hospitals perceived greater support for 
CDTM from the hospital staff as compared to pharmacy directors in hospitals owned by 
the government.  Hospitals with CDTM had significantly higher perceptions of support 
for CDTM if they had larger bed sizes and were situated in more populated cities. 
Similarly, significant associations also exist between the strategic impact of CDTM and 
institution ownership, bed size, and the population of the city in which the institution was 
located, with pharmacy directors of private hospitals that had a larger number of beds and 
were situated in more densely populated cities perceiving a significantly higher strategic 
impact of CDTM as compared to pharmacy directors of government hospitals that were 
smaller in size.  This in turn would cause the upper administration and medical staff at 
the hospitals to be more supportive of CDTM, which is then perceived by the pharmacy 
directors as being high. 
Significant associations also exist between the support for CDTM scale scores 
and Pharmacy Director Certification and degree.  Newman-Keuls multiple means 
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comparison tests found that pharmacy directors who had completed some certification 
related to the field perceived greater support for CDTM at their facilities compared to 
pharmacy directors that did not have any certification.  It was also seen that pharmacy 
directors that had a Pharm.D.  or a Doctor of Pharmacy degree perceived greater support 
for CDTM as compared to pharmacy directors with any other degree. 
Future Plans for CDTM activities 
In terms of the distribution of responses to the items on "Plans Regarding 
CDTM", the distribution was heavily skewed towards the right, with almost no 
respondents choosing the "Large decrease" or "Slight Decrease" option on the rating 
scale which indicates that all hospitals surveyed planned in both the short- term and long-
term for zero to some increase in the number of staff pharmacists involved in CDTM, 
number of CDTM protocols, and number of diseases or areas for which pharmacists 
provide CDTM, and almost no hospitals had plans for a decrease in the number of staff 
pharmacists involved in CDTM, number of CDTM protocols, and number of diseases or 
areas for which pharmacists provide CDTM .  However, hospitals with CDTM indicated 
larger planned increases than did hospitals without CDTM.  These findings are consistent 
with past literature where hospitals with CDTM were reported as being more likely to 
have plans for increase in CDTM involvement in the future (Thomas et al. 2003).  
Perceived Barriers and Facilitators for CDTM. 
  Lack of support from physicians and other medical staff (33.84%), shortage of 
pharmacists, financial or reimbursement issues (12.63%) and pharmacist time constraints 
(12.12%) were cited as the most frequent barriers to adopting CDTM.  Physician and 
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other medical staff support (42.20%), upper administration support (14.22%), and 
improvement in patient outcomes/reduction in medication errors (10.55%) were the most 
frequently mentioned facilitators of CDTM.  It is worth noting that physician support was 
both the most commonly cited facilitator as well as the most commonly cited barrier to 
CDTM.  It was also seen that pharmacy directors in hospitals with CDTM perceived a 
higher level of support from their medical staff as did pharmacy directors of hospitals that 
did not have CDTM.  This could be the reason why physician support was identified as 
both a barrier and a facilitator to CDTM.  Pharmacy directors of hospitals with CDTM 
would be expected to cite physician support as a facilitator while directors of hospitals 
without CDTM would cite it as a barrier.  Since CDTM has been found to be associated 
with significantly improved patient outcomes, physicians who have had past experience 
with CDTM would be expected to be more supportive of the practice, which is reflected 
in these results. 
This paradoxical choosing of physician support as both a major barrier and a 
major facilitator for CDTM was also seen in the 2003 survey by Thomas and colleagues 
(Thomas et al. 2003).  Respondents in the 2003 study identified a shortage of pharmacists 
and lack of support from physicians and other medical staff as the major perceived 
barriers to CDTM which are consistent with the finding of this study, although financial 
or reimbursement issues and pharmacist time constraints were also identified as major 
barriers to CDTM in this study in addition to the aforementioned barriers. 
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Limitations  
The present study had some limitation.  The survey response rate was 30.1 
percent.  A higher response rate would ensure a better representation of the population. 
However it is to be noted that evaluation of potential non-response bias indicated that 
there were no significant differences between early and late respondents in the proportion 
of hospitals that engaged in CDTM or in perceptions regarding CDTM.  The bed size 
distribution in the sample was also not found to differ significantly from the bed size 
distribution of the population. Therefore the sample can be assumed to be a good 
representation of the population.  All data collected on the scope and extent of CDTM 
were based on respondents’ self-reports and are dependent on the accuracy of their 
reports.  However, the pharmacy director should be a reliable source for information 
about the extent and scope of CDTM in a hospital. The perceptions of pharmacy directors 
were measured using an instrument that has only been used in one prior study. However, 
the instrument scales demonstrated good internal consistency when validated in a prior 
study 
 Implications 
Pharmacist CDTM  is characterized by an inter-disciplinary approach involving 
an agreement between patients and physicians to manage drug therapy regimens (Finley 
2002), in which qualified pharmacists are "permitted to assume responsibility for 
performing patient assessments, ordering drug therapy-related laboratory tests, 
administering drugs; and selecting, initiating, monitoring, continuing, and adjusting drug 
regimens" (Anaya 2008).   
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The scope of Pharmacy Practice has expanded over the last ten years (Giberson et 
al.  2011 ; Taylor 2008).  A report to the US Surgeon General in 2009 states that after a 
patient has received a confirmed diagnosis, the patient health care team generally 
includes several pharmacists that help the patient to manage their disease and also deliver 
patent care services as health care providers in the United States (Giberson et al.  2011).  
However, according to George Halvorson, chairman and CEO of the Kaiser Foundation 
Health Plan, Inc. clinical pharmacists are still "the most underutilized members of the 
health care team.” (Giberson et al.  2011). 
Although past studies have reported significant positive patient outcomes as a 
result of providing CDTM based care (Gattis 1999; Kalisch 2010; Duncan 2006),  the 
extent and scope of collaborative practice in hospital settings has considerable room for 
growth.  This study findings show that only 65 percent of all hospitals have CDTM.  
Since implementation of CDTM included pharmacist duties sometimes considered to be 
outside their normal scope of practice, each state is required to establish state specific 
laws that control the kind of care provided under CDTM, including the practice sites at 
which CDTM is allowed, the treatment/disease categories for which collaborative 
practice protocols can be defined as well as the kind of services pharmacists can provide 
under CDTM agreements (Finley et al.  2002).  The Practice Advisory on Collaborative 
Drug Therapy Management, which was approved by Academy of Managed Care 
Pharmacy in February 2012, states that forty-eight states currently have collaborative 
drug therapy management (CDTM) legislation or regulations (Weaver 2014).  However 
there is considerable variation in the way different states define the  pharmacist scope of 
practice under CDTM.  As of 2014, thirty-eight states allow pharmacists to initiate drug 
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therapy, and forty-five states authorize pharmacists to modify drug therapy.  Twenty-nine 
states make it mandatory for each collaborative agreement protocol to define particular 
medications or treatment/disease states/conditions for which the pharmacist is authorized 
to  manage drug therapy  under that protocol.  These limitations on practice are reflected 
in our study findings which show that the extent of CDTM activities by pharmacists 
varies with disease or treatment area.   
This study found that approximately 65 percent of respondent hospitals had some 
pharmacists engaged in CDTM. However reimbursement for CDTM activities was only 
received by nine percent of all hospitals.  This could have implications on the future of 
CDTM because lack of reimbursement for CDTM activities could discourage 
pharmacists from participating in CDTM.  The current push for provider status for 
pharmacists across the country seeks to address this issue (Weaver 2014).  The goal of 
this campaign is to have pharmacists designated as patient-care providers which would 
make them eligible to receive reimbursement under Medicare. The passage of this 
legislation requires an act of Congress, and if passed, it would enable pharmacists to 
billed for services provided as part of  CDTM.  California recently became the first state 
to pass this bill.  According to Stacie Maass, APhA Senior Vice President of Pharmacy 
Practice and Government Affairs, pharmacist involvement in collaborative practice at the 
state level will be instrumental in the passage of federal legislation that provides provider 
status to pharmacists since the number of pharmacists already involved in collaborative 
practice is being highlighted in front of Members of Congress by the pharmacist 
associations that are currently lobbying for provider status for pharmacists (Weaver 
2014).   This study's findings provide evidence about the number of pharmacists that are 
139 
currently involved in CDTM as well as the kind of activities already being carried out by 
pharmacists.  Although CDTM was not perceived to have any financial impact on 
pharmacy practice, it was perceived to have a positive strategic impact by raising the 
value of pharmacists in the eyes of the upper administration regarding and also by 
making it easier to implement other pharmacy services.  If medical staff and upper 
administration are convinced of the value of pharmacists, they could help in the effort to 
push for provider status, which would provide incentive for CDTM, which in turn would 
benefit patients.  
In addition to aiding the push for provider status, the study findings also indicate 
what the major barriers and facilitators to the adoption of CDTM in practice have been so 
far, as per pharmacy directors.  Knowledge of barriers and facilitators could help inform 
policy change in order to increase the scope of CDTM.  Assessing the current opinions of 
pharmacy directors on various aspects of CDTM can further help in identifying potential 




Cranor CW, Bunting BA, Christensen DB. The Asheville Project: Long-Term Clinical 
and Economic Outcomes of a Community Pharmacy Diabetes Program. J Am 
Pharm Assoc. 2003; 43: 173-84. 
De Oliveira DR, Brummel AR, Miller DB. Medication therapy management: 10 years of 
experience in a large integrated health care system. J Manag Care Pharm. 2010; 
16(3): 185-95. 
Dillman DA. Mail and internet surveys, the tailored design method. 2nd ed. New York: 
John Wiley & Sons, 2007. 
Fera T, Bluml BM, Ellis WM, Schaller CQ, Garret DG. The diabetes ten city challenge: 
interim clinical and humanistic outcomes of a multisite community pharmacy 
diabetes program. J Am Pharm Assoc. 2008; 48: 181–190. 
Finley PR, Bluml BM, Bunting BA, Kiser SN. Clinical and economic outcomes of a pilot 
project examining pharmacist-focused collaborative care treatment for depression. 
J Am Pharm Assoc. 2011; 51: 40–49. 
Gattis WA, Hasselblad V, Whellan DJ et al. Reduction in heart failure events by the 
addition of a clinical pharmacist to the heart failure management team: Results of 
the pharmacist in heart failure assessment recommendation and monitoring 
(PHARM) Study. Arch Intern Med 1999; 159:  1939–1945. 
Gerber RA, Liu G, McCombs JS. Impact of pharmacist consultations provided to patients 
with diabetes on healthcare costs in a health maintenance organization. Am J 
Manag Care. 1998; 4(7): 991-1000. 
Giberson S, Yoder S, Lee MP. Improving Patient and Health System Outcomes through 
Advanced Pharmacy Practice. A Report to the U.S. Surgeon General. Office of 
the Chief Pharmacist. U.S. Public Health Service. Dec 2011. 
Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med. 2006; 
160: 523-8. 
Institute of Medicine, Committee on Identifying and Preventing Medication Errors, 
Preventing Medication Errors. National Academies Press; 2007: 124-25 
Irons BK, Lenz RJ, Anderson SL, Wharton B, Habeger B, Anderson G: Retrospective 
cohort analysis of the clinical effectiveness of a physician-pharmacist 
collaborative drug therapy management diabetes clinic. Pharmacotherapy  
2002, 22: 1294-1300 
148 
 
Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, Brown LM, 
Cipolle RJ. Clinical and economic outcomes of medication therapy management 
services: the Minnesota experience. J Am Pharm Assoc. 2008; 48: 203–211. 
Leal S, Glover JJ, Herrier RN, Felix A: Improving quality of care in diabetes through a 
comprehensive pharmacist-based disease management program. Diabetes Care 
 27: 2983 –2984, 2004 
Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication 
adherence and persistence, blood pressure, and low-density lipoprotein 
cholesterol: a randomized controlled trial. J Am Pharm Assoc. 2006; 296(21): 
2563-2571. 
Menighan, Thomas E., " Obtaining Value Recognition and Compensation of Pharmacists 
Clinical Services", American Pharmacists Association. January 7, 2013. 
Report of the Task Force on the Delivery of Diabetes Self-Management Education and 
Medical Nutrition Therapy. Diabetes Spectrum. 1999; 12(1). 
Schumock et al. Economic evaluations of clinical pharmacy service (1988–1995). 
Pharmacotherapy 1996; 16: 1188–208.  
8. Johnson and Bootman. Drug-Related Morbidity and Mortality. Archives of 







 SELECTED BIBLIOGRAPHY 
Bedouch, P., M. Roustit, S. Quetant, C. Chapuis, M. Baudrant-Boga, A. Lehmann, C. 
Saint-Raymond, C. Pison and B. Allenet (2011). "Development of a pharmacist 
collaborative care program for pulmonary arterial hypertension." Int J Clin Pharm 
33(6): 898-901. 
 
Bondesson, A., T. Eriksson, A. Kragh, L. Holmdahl, P. Midlov and P. Hoglund (2013). 
"In-hospital medication reviews reduce unidentified drug-related problems." Eur J 
Clin Pharmacol 69(3): 647-655. 
 
Bouwmeester, C. and C. Chim (2013). "Pharmacist-managed oral anticoagulation therapy 
in the community setting." Consult Pharm 28(5): 280-294. 
 
Chen, Z., M. E. Ernst, G. Ardery, Y. Xu and B. L. Carter (2013). "Physician-pharmacist 
co-management and 24-hour blood pressure control." J Clin Hypertens 
(Greenwich) 15(5): 337-343. 
 
Chui, M. A., J. A. Stone, O. K. Odukoya and L. Maxwell (2014). "Facilitating 
collaboration between pharmacists and physicians using an iterative interview 
process." J Am Pharm Assoc (2003) 54(1): 35-41. 
 
Chung, C., A. Collins and N. Cui (2011). "Development and implementation of an 
interdisciplinary oncology program in a community hospital." Am J Health Syst 
Pharm 68(18): 1740-1747. 
 
Cranor CW, Bunting BA, Christensen DB. The Asheville Project: Long-Term Clinical 
and Economic Outcomes of a Community Pharmacy Diabetes Program. J Am 
Pharm Assoc. 2003; 43: 173-84. 
De Oliveira DR, Brummel AR, Miller DB. Medication therapy management: 10 years of 
experience in a large integrated health care system. J Manag Care Pharm. 2010; 
16(3): 185-95. 
Dillman DA. Mail and internet surveys, the tailored design method. 2nd ed. New York: 
John Wiley & Sons, 2007. 
Conley, M. P., C. Chim, C. E. Magee and D. J. Sullivan (2014). "A review of advances in 
collaborative pharmacy practice to improve adherence to standards of care in 
diabetes management." Curr Diab Rep 14(3): 470.
150 
 
Demik, D. E., M. W. Vander Weg, E. S. Lundt, C. S. Coffey, G. Ardery and B. L. Carter 
(2013). "Using theory to predict implementation of a physician-pharmacist 
collaborative intervention within a practice-based research network." Res Social 
Adm Pharm 9(6): 719-730. 
 
Drummond, N., K. Abbott, T. Williamson and B. Somji (2012). "Interprofessional 
primary care in academic family medicine clinics: implications for education and 
training." Can Fam Physician 58(8): e450-458. 
 
Earl, G. L. and J. A. Henstenburg (2012). "Dietary approaches to hypertension: a call to 
pharmacists to promote lifestyle changes." J Am Pharm Assoc (2003) 52(5): 637-
645. 
 
Farland, M. Z., D. C. Byrd, M. S. McFarland, J. Thomas, A. S. Franks, C. M. George, B. 
N. Gross, A. B. Guirguis and K. J. Suda (2013). "Pharmacist-physician 
collaboration for diabetes care: the diabetes initiative program." Ann 
Pharmacother 47(6): 781-789. 
 
Fera T, Bluml BM, Ellis WM, Schaller CQ, Garret DG. The diabetes ten city challenge: 
interim clinical and humanistic outcomes of a multisite community pharmacy 
diabetes program. J Am Pharm Assoc. 2008; 48: 181–190. 
Finley PR, Bluml BM, Bunting BA, Kiser SN. Clinical and economic outcomes of a pilot 
project examining pharmacist-focused collaborative care treatment for depression. 
J Am Pharm Assoc. 2011; 51: 40–49. 
Fletcher, G. F., K. Berra, B. J. Fletcher, L. Gilstrap and M. J. Wood (2012). "The 
integrated team approach to the care of the patient with cardiovascular disease." 
Curr Probl Cardiol 37(9): 369-397. 
 
Fortney, J. C., J. M. Pyne, S. B. Mouden, D. Mittal, T. J. Hudson, G. W. Schroeder, D. K. 
Williams, C. A. Bynum, R. Mattox and K. M. Rost (2013). "Practice-based versus 
telemedicine-based collaborative care for depression in rural federally qualified 
health centers: a pragmatic randomized comparative effectiveness trial." Am J 
Psychiatry 170(4): 414-425. 
 
Gattis WA, Hasselblad V, Whellan DJ et al. Reduction in heart failure events by the 
addition of a clinical pharmacist to the heart failure management team: Results of 
the pharmacist in heart failure assessment recommendation and monitoring 
(PHARM) Study. Arch Intern Med 1999;159: 1939–1945. 
Gerber RA, Liu G, McCombs JS. Impact of pharmacist consultations provided to patients 
with diabetes on healthcare costs in a health maintenance organization. Am J 
Manag Care. 1998; 4(7): 991-1000. 
151 
 
Giberson S, Yoder S, Lee MP. Improving Patient and Health System Outcomes through 
Advanced Pharmacy Practice. A Report to the U.S. Surgeon General. Office of 
the Chief Pharmacist. U.S. Public Health Service. Dec 2011. 
Health and Nutrition Examination Survey, 1999-2002. Arch Pediatr Adolesc Med. 2006; 
160: 523-8. 
Henry, T. M., S. Smith and M. Hicho (2013). "Treat to goal: impact of clinical 
pharmacist referral service primarily in diabetes management." Hosp Pharm 
48(8): 656-661. 
 
Howard-Thompson, A., M. Z. Farland, D. C. Byrd, A. Airee, J. Thomas, J. Campbell, R. 
Cassidy, T. Morgan and K. J. Suda (2013). "Pharmacist-physician collaboration 
for diabetes care: cardiovascular outcomes." Ann Pharmacother 47(11): 1471-
1477. 
 
Institute of Medicine, Committee on Identifying and Preventing Medication Errors, 
Preventing Medication Errors. National Academies Press; 2007: 124-25 
Irons BK, Lenz RJ, Anderson SL, Wharton B, Habeger B, Anderson G: Retrospective 
cohort analysis of the clinical effectiveness of a physician-pharmacist 
collaborative drug therapy management diabetes clinic. Pharmacotherapy  
2002, 22: 1294-1300 
Isetts BJ, Schondelmeyer SW, Artz MB, Lenarz LA, Heaton AH, Wadd WB, Brown LM, 
Cipolle RJ. Clinical and economic outcomes of medication therapy management 
services: the Minnesota experience. J Am Pharm Assoc. 2008; 48: 203–211. 
Jackson, A. N., K. K. Orr, J. P. Bratberg and F. Silverblatt (2014). "Pharmacist initiation 
of postexposure doxycycline for Lyme disease prophylaxis." J Am Pharm Assoc 
(2003) 54(1): 69-73. 
 
Jacobs, M., P. S. Sherry, L. M. Taylor, M. Amato, G. R. Tataronis and G. Cushing 
(2012). "Pharmacist Assisted Medication Program Enhancing the Regulation of 
Diabetes (PAMPERED) study." J Am Pharm Assoc (2003) 52(5): 613-621. 
 
Kelly, D. V., L. Bishop, S. Young, J. Hawboldt, L. Phillips and T. M. Keough (2013). 
"Pharmacist and physician views on collaborative practice: Findings from the 
community pharmaceutical care project." Can Pharm J (Ott) 146(4): 218-226. 
 
Kennie-Kaulbach, N., B. Farrell, N. Ward, S. Johnston, A. Gubbels, T. Eguale, L. 
Dolovich, D. Jorgenson, N. Waite and N. Winslade (2012). "Pharmacist provision 
of primary health care: a modified Delphi validation of pharmacists' 




Komanduri, K. V. (2013). "Pharmacists and physicians in hematopoietic stem cell 
transplantation: advances and opportunities to use collaborative practice 
agreements to improve care." Biol Blood Marrow Transplant 19(4): 505-506. 
 
Kucukarslan, S., S. Lai, Y. Dong, N. Al-Bassam and K. Kim (2011). "Physician beliefs 
and attitudes toward collaboration with community pharmacists." Res Social Adm 
Pharm 7(3): 224-232. 
 
Kulchaitanaroaj, P., J. M. Brooks, G. Ardery, D. Newman and B. L. Carter (2012). 
"Incremental costs associated with physician and pharmacist collaboration to 
improve blood pressure control." Pharmacotherapy 32(8): 772-780. 
 
Lalonde, L., E. Hudon, J. Goudreau, D. Belanger, J. Villeneuve, S. Perreault, L. Blais and 
D. Lamarre (2011). "Physician-pharmacist collaborative care in dyslipidemia 
management: the perception of clinicians and patients." Res Social Adm Pharm 
7(3): 233-245. 
 
Leal S, Glover JJ, Herrier RN, Felix A: Improving quality of care in diabetes through a 
comprehensive pharmacist-based disease management program. Diabetes Care 
 27: 2983 –2984, 2004 
Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication 
adherence and persistence, blood pressure, and low-density lipoprotein 
cholesterol: a randomized controlled trial. J Am Pharm Assoc. 2006; 296(21): 
2563-2571. 
Legault, F., J. Humbert, S. Amos, W. Hogg, N. Ward, S. Dahrouge and L. Ziebell (2012). 
"Difficulties encountered in collaborative care: logistics trumps desire." J Am 
Board Fam Med 25(2): 168-176. 
 
Lo, M. C., M. Freeman and M. C. Lansang (2013). "Effect of a multidisciplinary-assisted 
resident diabetes clinic on resident knowledge and patient outcomes." J Grad Med 
Educ 5(1): 145-149. 
 
Maddux, M. S. (2013). "Board of Regents commentary. Qualifications of pharmacists 
who provide direct patient care: perspectives on the need for residency training 
and board certification." Pharmacotherapy 33(8): 888-891. 
 
Makowsky, M. J., H. M. Madill, T. J. Schindel and R. T. Tsuyuki (2013). "Physician 
perspectives on collaborative working relationships with team-based hospital 
pharmacists in the inpatient medicine setting." Int J Pharm Pract 21(2): 123-127. 
 
Menas, P., D. Merkel, W. Hui, J. Lawton, A. Harper and G. Carro (2012). "Incidence and 
management of arthralgias in breast cancer patients treated with aromatase 
inhibitors in an outpatient oncology clinic." J Oncol Pharm Pract 18(4): 387-393. 
153 
 
Merten, J. A., J. F. Shapiro, A. M. Gulbis, K. V. Rao, J. Bubalo, S. Lanum, A. M. 
Engemann, S. Shayani, C. Williams, H. Leather and T. Walsh-Chocolaad (2013). 
"Utilization of collaborative practice agreements between physicians and 
pharmacists as a mechanism to increase capacity to care for hematopoietic stem 
cell transplant recipients." Biol Blood Marrow Transplant 19(4): 509-518. 
 
Menighan, Thomas E., " Obtaining Value Recognition and Compensation of Pharmacists 
Clinical Services", American Pharmacists Association. January 7, 2013. 
Moore, A., C. Patterson, J. White, S. T. House, J. J. Riva, K. Nair, A. Brown, A. Kadhim-
Saleh and D. McCann (2012). "Interprofessional and integrated care of the elderly 
in a family health team." Can Fam Physician 58(8): e436-441 
 
Murawski, M., K. R. Villa, E. J. Dole, T. J. Ives, D. Tinker, V. J. Colucci and J. Perdiew 
(2011). "Advanced-practice pharmacists: practice characteristics and 
reimbursement of pharmacists certified for collaborative clinical practice in New 
Mexico and North Carolina." Am J Health Syst Pharm 68(24): 2341-2350. 
 
Odum, L. and A. Whaley-Connell (2012). "The Role of Team-Based Care Involving 
Pharmacists to Improve Cardiovascular and Renal Outcomes." Cardiorenal Med 
2(4): 243-250. 
 
Oji, V., Y. McKoy-Beach, T. Pagan, B. Matike and O. Akiyode (2012). "Injectable 
administration privileges among pharmacists in the United States." Am J Health 
Syst Pharm 69(22): 2002-2005. 
 
Padiyara, R. S., J. J. D'Souza and R. S. Rihani (2011). "Clinical pharmacist intervention 
and the proportion of diabetes patients attaining prevention objectives in a 
multispecialty medical group." J Manag Care Pharm 17(6): 456-462. 
 
Pedersen, C. A., P. J. Schneider and D. J. Scheckelhoff (2013). "ASHP national survey of 
pharmacy practice in hospital settings: monitoring and patient education--2012." 
Am J Health Syst Pharm 70(9): 787-803. 
 
Report of the Task Force on the Delivery of Diabetes Self-Management Education and 
Medical Nutrition Therapy. Diabetes Spectrum. 1999; 12(1). 
Ripley, T. L., P. B. Adamson, T. A. Hennebry, J. S. Van Tuyl, D. L. Harrison and R. C. 
Rathbun (2013). "Collaborative Practice Model Between Cardiologists and 
Clinical Pharmacists for Management of Patients With Cardiovascular Disease in 
an Outpatient Clinic." Ann Pharmacother. 
 
Ross, L. A. (2011). "Pharmacists as mid-level practitioners/providers." Ann 
Pharmacother 45(6): 810-812. 
154 
 
Salvo, M. C. and A. M. Brooks (2012). "Glycemic control and preventive care measures 
of indigent diabetes patients within a pharmacist-managed insulin titration 
program vs standard care." Ann Pharmacother 46(1): 29-34. 
 
Samp, J. C., D. R. Touchette, J. S. Marinac and G. M. Kuo (2013). "Economic Evaluation 
of the Impact of Medication Errors Reported by U.S. Clinical Pharmacists." 
Pharmacotherapy. 
 
Schumock et al. Economic evaluations of clinical pharmacy service (1988–1995). 
Pharmacotherapy 1996; 16:1188–208.  
8. Johnson and Bootman. Drug-Related Morbidity and Mortality. Archives of 
Internal Medicine. 1995; 155: 1949-1956. 
Sease, J. M., M. A. Franklin and K. R. Gerrald (2013). "Pharmacist management of 
patients with diabetes mellitus enrolled in a rural free clinic." Am J Health Syst 
Pharm 70(1): 43-47. 
 
Serper, M., D. M. McCarthy, R. E. Patzer, J. P. King, S. C. Bailey, S. G. Smith, R. M. 
Parker, T. C. Davis, D. P. Ladner and M. S. Wolf (2013). "What patients think 
doctors know: beliefs about provider knowledge as barriers to safe medication 
use." Patient Educ Couns 93(2): 306-311. 
 
Shannon, S. B., L. R. Bradley-Baker and H. A. Truong (2012). "Pharmacy residencies 
and dual degrees as complementary or competitive advanced training 
opportunities." Am J Pharm Educ 76(8): 145. 
 
Skelton, J. B. (2011). "Pharmacist-provided immunization compensation and recognition: 
white paper summarizing APhA/AMCP stakeholder meeting." J Am Pharm Assoc 
(2003) 51(6): 704-712. 
 
St Peter, W. L., T. M. Farley and B. L. Carter (2011). "Role of collaborative care models 
including pharmacists in improving blood pressure management in chronic kidney 
disease patients." Curr Opin Nephrol Hypertens 20(5): 498-503. 
 
Thomas, J., M. Bharmal, S.-W. Lin and Y. Punekar (2006). "Survey of pharmacist 
collaborative drug therapy management in hospitals." American Journal of 
Health-System Pharmacy 63(24): 2489-2499. 
 
Thompson, C. A. (2011). "Collaborative practice comes to New York, expands in 
Indiana." Am J Health Syst Pharm 68(14): 1278, 1288. 
 
Valero Garcia, S., E. Lopez Briz, P. Escobar Cava, J. Balaguer, A. Pelufo, J. E. Megias 
and J. L. Poveda Andres (2013). "Selective ophthalmic intra-arterial melphalan 
therapy for advanced retinoblastoma: implementation and outcomes of a new 
chemotherapy protocol." J Oncol Pharm Pract 19(2): 159-164. 
155 
 
Van, C., D. Costa, B. Mitchell, P. Abbott and I. Krass (2013). "Development and 
validation of a measure and a model of general practitioner attitudes toward 
collaboration with pharmacists." Res Social Adm Pharm 9(6): 688-699. 
 
Via-Sosa, M. A., N. Lopes and M. March (2013). "Effectiveness of a drug dosing service 
provided by community pharmacists in polymedicated elderly patients with renal 
impairment--a comparative study." BMC Fam Pract 14: 96. 
 
Wheeler, A., K. Crump, M. Lee, L. Li, A. Patel, R. Yang, J. Zhao and M. Jensen (2012). 
"Collaborative prescribing: a qualitative exploration of a role for pharmacists in 
mental health." Res Social Adm Pharm 8(3): 179-192. 
 
Zargarzadeh, A. H., S. Jacob, R. S. Klotz and F. T. Khasawneh (2011). "Clinical 
pharmacists and basic scientists: do patients and physicians need this 





Appendix A. Study Survey
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SECTION I:  ABOUT COLLABORATIVE PRACTICE 
1.  Collaborative practice, also referred to more specifically as collaborative drug therapy 
management, often involves initiating or modifying drug therapy.  Do pharmacists in 
your hospital engage in collaborative practice that involves initiation or modification 
of drug therapy, i.e., active intervention beyond a written consult or general 
therapeutic interchange protocols? 
   Yes 
  No (If no, please go to Section II on Page 3) 
2.  Please indicate if any pharmacists in your institution are authorized to do each of the 
following activities and if each activity can be performed for only some patients or for 
all patients. (Please respond for each item. 
Yes    No 
___   ___ 
         Initiate drug therapy   
         Change duration of a drug therapy   
         Adjust a drug’s strength   
         Change a drug’s dosage form   
         Change a drug’s frequency of administration   
         Change a drug’s route of administration   
         Hold a drug   
         Discontinue a drug   
         Order laboratory or related tests   
         Other (please specify) ______________________________   
3.  Please indicate the total number of pharmacists employed in your institution and the 
number of pharmacists in collaborative practice. 
_______ Total number of pharmacists 
_______ Number of pharmacists engaged in collaborative practice 






























4.  Does your institution have written protocols for collaborative practice that involves 
initiation or modification of drug therapy? 
  Yes If yes, how many? _______________ (Please continue to Question 5) 
  No (If no, please go to Question 6) 
5.  Please indicate whether protocols in your institution for collaborative practice that 
involves initiation or modification of drug therapy are disease/treatment specific or 
general (check all that apply) 
  Protocols are disease and/or treatment-specific 
  Protocols are general for several diseases and/or treatments 
  Other (please specify) ______________________________________________ 
6.  For what diseases and/or treatments do pharmacists in your hospital engage in 
collaborative practice that involves initiation or modification of drug therapy, i.e., 
active intervention beyond a written consult or general therapeutic interchange 
protocols? (Check all that apply.) 
Yes    No 
        Anticoagulation                                            
        Diabetes                                            
        Hypertension                                           
        Asthma                                           
        Emergency contraception                                          
              Dyslipidemias                                           
        Heart failure                                            
        Infectious disease                                            
        General medicine                                            
        Smoking cessation                                           






































































































































        Parenteral nutrition                                           
        Immunization                                            
        Other _______________                                            
        Other _______________                                           
        Other _______________                                          
  
7.  Are patients charged a fee for any pharmacists’ collaborative practice activities? 
  Yes    If yes,    inpatient only      outpatient only      inpatient and outpatient 
  No 
8.  Does your pharmacy receive insurance reimbursement for any collaborative practice 
activities? 
  Yes      (If yes, please specify which activities.)  
________________________________________ 
  No                                                                         
                                                                              
________________________________________ 
Section II.  Opinions About Current Practice 
Based on your experience, please indicate your agreement or disagreement with each of 
the following statements about collaborative practice that involves pharmacist initiation 
or modification of drug  
therapy, i.e., active intervention beyond a written consult or general therapeutic 
interchange protocols, (CP) by rating each item from 1 to 5 where 1= Strongly disagree, 
2=Disagree, 3= Neutral, 4= Agree,  
and  5 =Strongly agree. 
Range and Type of Activities 
1.  The range of diseases in which collaborative practice 
 involving pharmacist initiation or modification 
 of drug therapy (CP) is applied is too narrow 1 2 3 4 5 
2.  Pharmacists who provide CP have access to 
 necessary patient medical records without any difficulty  1 2 3 4 5   
3.  Pharmacist should have prescribing authority independent of 
physician-approved protocol 1 2 3 4 5 
4.  The range of decisions that may be  

































Section II.  Opinions About Current Practice Cont’d 
5.  My hospital’s protocols on CP are clear 1 2 3 4 5 
6.  My hospital’s protocols on CP are too restrictive 1 2 3 4 5 
Support for CP 
1.  Upper hospital administration is supportive of CP 1 2 3 4 5 
2.  Physicians in my institution are not supportive of CP 1 2 3 4 5 
3.  The pharmacy staff is supportive of CP 1 2 3 4 5 
4.  CP enhances the relationship between pharmacists  
 and physicians 1 2 3 4 5 
5.  I am supportive of our pharmacists being involved in CP 
6.  CP impairs relationships between pharmacists 
 who provide CP and those who do not 1 2 3 4 5 
7.  My management staff is supportive of our pharmacists  1 2 3 4 5 
 being involved in CP 
8.  Nurses are supportive of our pharmacists being involved in CP 1 2 3 4 5 
9.  Patients appear comfortable with the expanded role of 1 2 3 4 5 
  pharmacists in CP 
Effects of CP 
1.  Providing collaborative services enhances upper administration’s 
 perceptions of the value of pharmacists 1 2 3 4 5 
2.  CP has facilitated implementation of other pharmacy services 1 2 3 4 5 
3.  Physicians have asked my staff pharmacists to provide 
 more advanced services because of CP  1 2 3 4 5 
Financial 
1.  CP has helped pharmacy maintain resources 1 2 3 4 5 
2.  Third party payers provide reimbursement for some CP activities 1 2 3 4 5 
3.  CP has helped pharmacy obtain more funds for staff salaries 1 2 3 4 5 
4.  CP has helped pharmacy limit reductions in resources 1 2 3 4 5 
5.  CP has helped the pharmacy department obtain more resources 1 2 3 4 5 
Regulation affecting CP 
1.  Current state regulations on CP are too restrictive 1 2 3 4 5 
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2.  Current state regulations on CP encourage CP 1 2 3 4 5  
3.  Current state regulations on CP do not need changes 1 2 3 4 5 
4.  Current regulations on CP inhibit CP 1 2 3 4 5 
Section III:  Future Plans for CP 
1.  Please indicate your short-term plans (within one year) 
  for CP by rating each of the following 
  based on the scale where 1= “large decrease” 
and 5=”large increase.” 
a)  Number of staff pharmacists involved in CP 1 2 3 4 5 
b)  Number of CP protocols 1 2 3 4 5 
c)  Number of diseases/ therapies in which 
 pharmacist provide CP 1 2 3 4 5 
2.  Please indicate your long-term plans  
(beyond one year) for CP by rating  
 each of the following based on the scale where 
1= “large decrease” and 5=”large increase.” 
a)  Number of staff pharmacists involved in CP  1 2 3 4 5 
b)  Number of CP protocols  1 2 3 4 5 
c)  Number of diseases/ therapies in which  
pharmacist provide CP  1 2 3 4 5 
 
3.  What has been the greatest barrier to CP? 
_____________________________________________________________________ 
















































































Section IV:  Demographics 
Part A- About your institution 
1.  Please indicate which of the following best describes your institution’s ownership? 
  Private (Non-profit) 
  Private (For-profit) 
  Government (City, county, state) 
2.  Please indicate which of the following best describes your institution’s classification: 
  Short-term general and other special 
  Long-term general and other special 
  Psychiatric (Mental health institution) 
  TB and other respiratory diseases 
  Other (please specify) _____________________________________________ 
3.  Please indicate the population of the city in which your institution is located. 
  Less than 1,000   25,000 to 49,999 
  1,000 to 1,499   50,000 to 99,999 
  1,500 to 2,499   100,000 to 249,999 
  2,500 to 4,999   250,000 to 499,999 
  5,000 to 9,999   500,000 to 999,999 
  10,000 to 24,999   More than 1 million 
4.  Please indicate the number of beds in your hospital. 
  6 to 24   200 to 299 
  25 to 49   300 to 399 
  50 to 99   400 to 499 
  100 to 199   More than 500 
5.  What was the total number of patient-days in your hospital last year?  ____________ 
(please see back of this sheet for last page) 
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Part B-About you 
1.  Please indicate your gender. 
  Female 
  Male 
2.  Please indicate your age. 
  Less than 25 years   45 to 54 years 
  25 to 34 years   55 to 64 years 
  35 to 44 years   More than 65 years 
3.  Please indicate educational degree(s) you have obtained (check all that apply) 
  Doctor of Pharmacy   M.S. 
  BS in Pharmacy   Ph.D. 
  Other (please specify)  ___________________________________ 
4.  Have you completed any pharmacy residency? 
  Yes     If yes,     General (pharmacy practice)       Specialty        Total Number 
completed ___ 
  No 
5.  How long has it been since you were first licensed to practice pharmacy? 
  Less than 1 year   5 to 10 years 
  1 to 3 years   10 to 15 years 
  3 to 5 years   More than 15 years 
6.  Do you have any special certification or recognition in pharmacy 
  Yes, the certification or recognition is _____________________________ 
  No 
Comments: 
Please use the space below and the following page to share any comments regarding 
pharmacist collaborative practice.  The information you provide will be kept confidential. 
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No postage is required to return this survey.  Simply refold it with the business 
reply side out, use a small piece of tape to keep it together and place it in any mailbox. 
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Appendix B:  Advance Notice Letter
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City, State   Zip 
Dear Pharmacy Director: 
A few days from now you will receive in the mail a request to fill out a brief 
questionnaire for a research project being conducted by Purdue University. 
It concerns pharmacist collaborative practice, also called collaborative drug therapy 
management, and it will be used to assess the current state of collaborative practice in 
hospitals 
I am writing in advance because we have found many people like to know ahead of time 
that they will be contacted.  Your institution was randomly selected as part of a national 
sample of hospitals.  Your responses are needed regardless of whether your institution 
has pharmacist engaged in such activities.  Your responses combined with those of other 
pharmacy directors will provide a picture of the current state of collaborative practice and 
likely future trends in this evolving part of pharmacy practice.   
Thank you for your time and consideration.  It is only with the generous help of people 
like you that our research can be successful. 
Sincerely, 













City, State   Zip 
Dear Pharmacy Director: 
Pharmacist collaborative practice or collaborative drug therapy management that involves 
pharmacist initiation and/or modification of drug therapy has received much attention as 
a means of improving medication use and outcomes.  We are working to assess the 
current state of collaborative practice in hospitals.  Please assist us in this effort by taking 
a few minutes to complete the enclosed survey designed to collect information on 
whether hospitals have pharmacists involved in such activities, what specific activities 
pharmacist engage in, in which disease areas such activities take place and the impact of 
such activities upon the strategic position of pharmacy services in hospitals. 
Your institution was randomly selected as part of a national sample of hospitals.  Your 
responses are needed regardless of whether your institution has pharmacist engaged in 
such activities.  Your responses combined with those of other pharmacy directors will 
provide a picture of the current state of collaborative practice and likely future trends in 
this evolving part of pharmacy practice.  There is a code number on surveys, but it only 
identifies the hospital so that we may follow-up on responses.  Only grouped anonymous 
data from the surveys will be reported without identification of any individual or 
institution. 
Return postage on the survey is prepaid.  After completing the survey, simply refold it 
with the business reply side out and seal with a small piece of tape before placing it in 
any mailbox.  Thank you. 
 
Sincerely, 













City, State   Zip 
Dear Pharmacy Director: 
About twelve weeks ago, you should have received a survey on pharmacist collaborative 
practice in hospitals.  Although you may have received a prior reminder about the survey, 
we are writing again because your individual response is very important.  Regardless of 
whether your institution has pharmacists engaged in such activities or the extent to which 
pharmacists are engaged in such activities, your responses are essential to the project 
findings reflecting the full range of hospitals. 
Please assist us in this effort by completing and returning the survey.  All information 
collected will be kept strictly confidential.  A code number on each survey, only 
identifies each hospital so that we may remove hospitals that have responded from 
follow-up mailings.  Only anonymous grouped data will be reported without 
identification of any individual or institution. 
Another copy of the survey is enclosed for your convenience.  Return postage is prepaid.  
Simply refold the completed survey with the business reply side out and seal with a small 
piece of tape before placing it in any mailbox.  Thank you very much for your assistance. 
Sincerely, 
Joseph Thomas III, Ph.D. Pragya Mishra 
Professor Graduate Student
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Appendix E:  Reminder Postcard  
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Postcard Thank you/Reminder 
 
 
Last week a questionnaire seeking your opinion on pharmacist collaborative practice in 
hospitals was sent to you.  Your institution was randomly selected as part of a national 
sample of hospitals 
If you have already completed and returned the questionnaire to us, please accept our 
sincere thanks.  If not,  please take a few minutes to do so today.  Your individual 
response is very important and essential to project findings reflecting the full range of 
hospitals, regardless of whether your institution has pharmacists engaged in such 
activities.  All information collected will be kept strictly confidential.  
If you did not receive a questionnaire, or if it was misplaced, please call us at------- and 
we will get another one in the mail to you today. 
 
 
Joseph Thomas III, Ph.D. Pragya Mishra 
Professor Pharmacy Student 
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Appendix F:  Sampling Fractions 
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Table F1. Sampling Fractions, Stratified by State 
__________________________________________________________________ 
State Hospital Number in Sampling   Rounded Off 
  Count List Fraction (N=1026) 
__________________________________________________________________ 
AK 21 8 3.26 3 
AL 129 48 20.07 20 
AR 100 37 15.56 16 
AZ 101 37 15.71 16 
CA 492 182 76.55 77 
CO 89 33 13.84 14 
CT 50 19 7.78 8 
DC 15 6 2.33 2 
DE 14 5 2.17 2 
FL 306 113 47.61 48 
GA 198 73 30.80 31 
HI 23 9 3.57 4 
IA 126 47 19.60 20 
ID 38 14 5.91 6 
IL 222 82 34.54 35 
IN 174 64 27.07 27 
KS 143 53 22.25 22 
KY 132 49 20.53 21 
LA 173 64 26.91 27 
MA 124 46 19.29 19 
MD 74 27 11.51 12 
ME 45 17 7.00 7 
MI 177 65 27.54 28 
MN 135 50 21.00 21 
MO 154 57 23.96 24 




Table F1. Contd. 
__________________________________________________________________ 
State Hospital Number in Sampling   Rounded Off 
  Count List Fraction (N=1026) 
__________________________________________________________________ 
MT 51 19 7.93 8 
NC 150 56 23.34 23 
ND 41 15 6.37 6 
NE 77 28 11.98 12 
NH 32 12 4.97 5 
NJ 113 42 17.58 18 
NM 55 20 8.55 9 
NV 53 20 8.24 8 
NY 263 97 40.92 41 
OH 235 87 36.56 37 
OK 147 54 22.87 23 
OR 63 23 9.80 10 
PA 269 100 41.85 42 
RI 17 6 2.64 3 
SC 104 38 16.18 16 
SD 51 19 7.93 8 
TN 169 63 26.29 26 
TX 606 224 94.29 94 
UT 49 18 7.62 8 
VA 133 49 20.69 21 
VT 15 6 2.33 2 
WA 110 41 17.11 17 
WI 147 54 22.87 23 
WV 66 24 10.26 10 
WY 30 11 4.66 5 
__________________________________________________________________
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Appendix G:  Distribution of Responses on Opinions about Collaborative Drug Therapy 
Management 
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Table G1.  Distribution of Responses on Opinions about Collaborative Drug Therapy Management (CDTM) 
____________________________________________________________________________________________________________  
  Number of Respondents choosing each Response  
  ________________________________________________________________________  
Response Strongly Disagree Disagree No Opinion Agree Strongly Agree 
____________________________________________________________________________________________________________  
Range and Type Of Activities   
The range of diseases in which collaborative 2 27 85 122 34 
practice involving pharmacist initiation or  
modification of drug therapy (CP)  
is applied is too narrow  
Pharmacists who provide CP have access to 4 22  29  77  138 
necessary patient medical records without  
any difficulty 
Pharmacist should have prescribing authority 16  47  87  76  44 
independent of physician-approved protocols 
 
The range of decisions that may be  35  132  92  8  1 
 made for patients in which CP occurs is 
too broad 
My hospital’s protocols on CP are clear 6  24  75  109  52 
 










  Percent of Respondents choosing each Response  
  ________________________________________________________________________  
Response Strongly Disagree Disagree No Opinion Agree Strongly Agree 
____________________________________________________________________________________________________________  
Support for CP 
Upper hospital administration  4  15  73 126  51 
is supportive of CP 
Physicians in my institution are not supportive  15 42 88 71 48 
of CP 
The pharmacy staff is supportive of CP 2 9 33 149 77 
CP enhances the relationship between  3 7 20 130 110 
pharmacists and physicians 
I am supportive of our pharmacists being  1 6 14 80 169 
involved in CP 
CP impairs relationships between pharmacists 40 87 87 39 16 
who provide CP and those who do not 
My management staff is supportive of  3 10 56 96 105 
our pharmacists being involved in CP 
Nurses are supportive of our pharmacists  1 6 54 108 101 






Table G1 Contd. 
____________________________________________________________________________________________________________  
  Number of Respondents choosing each Response  
  ________________________________________________________________________  
Response Strongly Disagree Disagree No Opinion Agree Strongly Agree 
____________________________________________________________________________________________________________  
Patients appear comfortable with the 0 0 88 122 45 
expanded role of pharmacists in CP 
Effects of CP 
Providing collaborative services enhances 0 1 38 133 91 
upper administration’s perceptions of the 
value of pharmacists  
CP has facilitated implementation of other 2 12 77 121 48 
pharmacy services  
Physicians have asked my staff pharmacists to 6 24 76 100 55provide more 
advanced services because of CP   
Financial 
CP has helped pharmacy maintain resources 10 27 101 79 39 
Third party payers provide reimbursement for 54 72 92 31 8 







Table G1 Contd. 
____________________________________________________________________________________________________________  
  Number of Respondents choosing each Response  
  ________________________________________________________________________  
Response Strongly Disagree Disagree No Opinion Agree Strongly Agree 
____________________________________________________________________________________________________________  
CP has helped pharmacy obtain more funds  37 88 99 24 6 
for staff salaries  
CP has helped pharmacy limit reductions in 25 49 103 66 14 
resources  
CP has helped the pharmacy department obtain  23 71 101 48 15 
more resources  
Regulation affecting CP 
Current state regulations on CP are too restrictive 2 44 110 73 34 
Current state regulations on CP encourage CP 12 49 135 60 6 
Current state regulations on CP do not need  29 93 116 24 1 
changes  
Current regulations on CP inhibit CP 9 54 143 39 18 
 _____________________________________________________________________________________________________________  
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